# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acknowledgements</td>
<td>4</td>
</tr>
<tr>
<td>About MDS</td>
<td>5</td>
</tr>
<tr>
<td>Purpose, Mission And Goals</td>
<td>5</td>
</tr>
<tr>
<td>MDS Officers (2011-2013)</td>
<td>6</td>
</tr>
<tr>
<td>MDS International Executive Committee</td>
<td>6</td>
</tr>
<tr>
<td>International Congress Oversight Committee</td>
<td>6</td>
</tr>
<tr>
<td>Congress Scientific Program Committee</td>
<td>6</td>
</tr>
<tr>
<td>Congress Local Organizing Committee</td>
<td>6</td>
</tr>
<tr>
<td>Past-Presidents</td>
<td>6</td>
</tr>
<tr>
<td>International Medical Society for Motor Disturbances Past-Presidents</td>
<td>6</td>
</tr>
<tr>
<td>MDS International Secretariat</td>
<td>6</td>
</tr>
<tr>
<td>International Congress Information</td>
<td>7</td>
</tr>
<tr>
<td>Dates</td>
<td>7</td>
</tr>
<tr>
<td>Official Language</td>
<td>7</td>
</tr>
<tr>
<td>Venue</td>
<td>7</td>
</tr>
<tr>
<td>Exhibition</td>
<td>7</td>
</tr>
<tr>
<td>Abstract Poster Sessions</td>
<td>7</td>
</tr>
<tr>
<td>Registration</td>
<td>7</td>
</tr>
<tr>
<td>Registration Confirmation</td>
<td>7</td>
</tr>
<tr>
<td>Cancellation/Refund Policy</td>
<td>7</td>
</tr>
<tr>
<td>Group Registration</td>
<td>7</td>
</tr>
<tr>
<td>Registration Desk</td>
<td>7</td>
</tr>
<tr>
<td>Scientific Sessions</td>
<td>7</td>
</tr>
<tr>
<td>Special Accessibility Needs</td>
<td>8</td>
</tr>
<tr>
<td>Camera Policy</td>
<td>8</td>
</tr>
<tr>
<td>Weather</td>
<td>8</td>
</tr>
<tr>
<td>Currency</td>
<td>8</td>
</tr>
<tr>
<td>Estimated Flight Times to Dublin, Ireland</td>
<td>8</td>
</tr>
<tr>
<td>Events</td>
<td>8</td>
</tr>
<tr>
<td>CME Information</td>
<td>9</td>
</tr>
<tr>
<td>Daily Schedule</td>
<td>10</td>
</tr>
<tr>
<td>Program-at-a-Glance</td>
<td>10</td>
</tr>
<tr>
<td>MDS 16th International Congress Session Definitions</td>
<td>11</td>
</tr>
<tr>
<td>Sunday, June 17, 2012</td>
<td>12</td>
</tr>
<tr>
<td>Monday, June 18, 2012</td>
<td>13</td>
</tr>
<tr>
<td>Tuesday, June 19, 2012</td>
<td>16</td>
</tr>
<tr>
<td>Wednesday, June 20, 2012</td>
<td>19</td>
</tr>
<tr>
<td>Thursday, June 21, 2012</td>
<td>22</td>
</tr>
<tr>
<td>Faculty Listing</td>
<td>25</td>
</tr>
<tr>
<td>Education Information</td>
<td>28</td>
</tr>
<tr>
<td>Membership Information</td>
<td>32</td>
</tr>
<tr>
<td>Top Attractions in Dublin</td>
<td>33</td>
</tr>
<tr>
<td>Housing</td>
<td>35</td>
</tr>
<tr>
<td>Important Dates</td>
<td>36</td>
</tr>
<tr>
<td>Save The Date</td>
<td>36</td>
</tr>
</tbody>
</table>
Dear Colleagues,

On behalf of The Movement Disorder Society, we are honored to formally invite you to attend the 16th International Congress of Parkinson’s Disease and Movement Disorders in Dublin, Ireland, from June 17-21, 2012.

The 2012 International Congress will be held in The Convention Centre Dublin, designed by Kevin Roche. This is Ireland’s world class, purpose built international conference and event venue. Prepare to experience a location like no other, right in the heart of Dublin (UNESCO City of Literature). We look forward to coming together to learn about the latest research and advancements, collaborate with colleagues and actively participate in the advancing field of Movement Disorders, all while enjoying the history, literature, sights, sounds, and tastes of ancient Dublin.

Dublin (from the Irish Gaelic An Dubh Linn meaning ‘the black pool’) was established as a Viking settlement on the River Liffey over 1,000 years ago. The Anglo-Norman and subsequent English invasions followed. During the Georgian period, when it was the second largest city in the British Empire, Dublin became an important European cultural centre. This rich and varied history has left an indelible mark on this colourful and atmospheric city. Today, Dublin is a bustling metropolis with a population of over 1.7 million. Home to over 100 different nationalities, it has a genuinely cosmopolitan feel and yet retains its own distinct culture, which is expressed in a love of literature, drama and traditional music.

We are delighted to welcome you to Dublin for the 16th International Congress and hope you will take the opportunity to be part of this exceptional Scientific Program. We promise an unparalleled learning opportunity.

With kind regards,

Günther Deuschl
President,
The Movement Disorder Society, 2011-2013

David John Burn
Chair,
Congress Scientific Program Committee, 2011-2013

Timothy Lynch
Co-Chair,
Congress Scientific Program Committee, 2012
ACKNOWLEDGEMENTS

The International Congress Oversight Committee of the 16th International Congress of Parkinson’s Disease and Movement Disorders wishes to acknowledge and thank the following companies for their support:

Platinum Plus Level

Platinum Level

Gold Level

Silver Level

Bronze Level

*These companies are confirmed as of January 25, 2012.
ABOUT MDS

The Movement Disorder Society (MDS) is an international, professional society of clinicians, scientists, and other healthcare professionals who are interested in Parkinson’s disease, related neurodegenerative and neurodevelopmental disorders, hyperkinetic movement disorders, and abnormalities in muscle tone and motor control. The spectrum of clinical disorders represented by the Society includes, but is not limited to:

- Ataxia
- Blepharospasm
- Dysphonia
- Dystonic disorders
- Gait disorders
- Huntington’s disease
- Myoclonus
- Parkinson’s disease
- Restless legs syndrome
- Spasticity
- Tardive dyskinesia
- Tics and Tourette syndrome
- Tremor

The Movement Disorder Society (MDS) was founded in 1985 on the initiative of Professors Stanley Fahn and C. David Marsden, whose leadership and vision guided the expansion of clinical expertise and research in this field. The organization merged in 1988 with the International Medical Society for Motor Disturbances.

Purpose, Mission And Goals

**Purpose:**
The objective and mission of the Society shall be to advance the neurological sciences pertaining to Movement Disorders; to improve the diagnosis and treatment of patients; to operate exclusively for scientific, scholarly and educational purposes; to encourage research; to provide forums, such as medical journals, scientific symposia and International Congresses, for sharing ideas and for advancing the related clinical and scientific disciplines; to encourage interest and participation in the activities of the Society among healthcare and allied professionals and scientists; and to collaborate with other related professional and lay organizations.

**Mission and Goals:**
To disseminate knowledge about Movement Disorders by:
- Providing educational programs for clinicians, scientists and the general public designed to advance scientific and clinical knowledge about Movement Disorders
- Sponsoring International Congresses and Symposia on Movement Disorders
- Collaborating with other international organizations and lay groups
- Publishing journals, videotapes and other collateral materials committed to high scientific standards and peer review

To promote research into causes, prevention and treatment of Movement Disorders by:
- Using the Society’s influence and resources to enhance support for research
- Facilitating the dissemination of information about research
- Encouraging the training of basic and clinical scientists in Movement Disorders and related disorders

For the purposes of favorably affecting the care of patients with Movement Disorders, the Society will provide expertise, advice and guidance to:
- Regulatory agencies to assist them in the approval process of safe and effective therapeutic interventions
- The public (media) and patient support groups by informing them of new research and therapeutic advances
- Governments to assist them in the development of policies that affect support of research and patient care
- Educational efforts to assist in developing standards of training in the specialty
ABOUT MDS

MDS Officers (2011-2013)

President
Günther Deuschl, Germany

President-Elect
Matthew Stern, USA

Secretary
Cynthia Comella, USA

Secretary-Elect
Francisco Cardoso, Brazil

Treasurer
Nir Giladi, Israel

Treasurer-Elect
Christopher Goetz, USA

Past-President
Philip Thompson, Australia

MDS International Executive Committee
Kailash Bhatia, United Kingdom
David John Burn, United Kingdom
Murat Emre, Turkey
Susan Fox, Canada
Victor Fung, Australia
Etienne Hirsch, France
Ryuji Kaji, Japan
Serge Przedborski, USA
Anthony H.V. Schapira, United Kingdom
A. Jon Stoessl, Canada

International Congress Oversight Committee
Chair: Anthony Lang, Canada
David John Burn, United Kingdom
Günther Deuschl, Germany
Nir Giladi, Israel
Andrew Lees, United Kingdom
Timothy Lynch, Ireland
Matthew Stern, USA
Philip Thompson, Australia

Congress Scientific Program Committee
Chair: David John Burn, United Kingdom
Co-Chair: Timothy Lynch, Ireland
Roger Barker, United Kingdom
Daniela Berg, Germany
Erwan Bezard, France
Kailash Bhatia, United Kingdom
Bastiaan Bloem, Netherlands
Francisco Cardoso, Brazil

Günther Deuschl, Germany
Giovanni Fabbrini, Italy
Joaquim Ferreira, Portugal
Susan Fox, Canada
Victor Fung, Australia
Oscar Gershanik, Argentina
Glenda Halliday, Australia
Christine Klein, Germany
Paul Krack, France
Anthony Lang, Canada
Irene Litvan, USA
Pablo Martinez-Martin, Spain
Marcelo Merello, Argentina
Jose Obeso, Spain
Per Odin, Germany
Lynn Rochester, United Kingdom
Robert Rodnitzky, USA
Klaus Seppi, Austria
Philip Starr, USA
Matthew Stern, USA
Antonio Strafella, Canada
D. James Surmeier, USA
Louis Tan, Singapore
Philip Thompson, Australia

Past-Presidents
2009-2011 Philip Thompson, Australia
2007-2009 Anthony Lang, Canada
2005-2006 Andrew Lees, United Kingdom
2003-2004 C. Warren Olanow, USA
2001-2002 Werner Poewe, Austria
1999-2000 Mark Hallett, USA
1997-1998 Eduardo Tolosa, Spain
1995-1996 Joseph Jankovic, USA
1991-1994 C. David Marsden, United Kingdom
1988-1991 Stanley Fahn, USA

International Medical Society for Motor Disturbances Past-Presidents
1993-1994 C. Warren Olanow, USA
1991-1992 Bastian Conrad, Germany
1989-1990 Mark Hallett, USA
1987-1988 Mario Manfredi, Italy
1985-1986 C. David Marsden, United Kingdom

MDS International Secretariat
The Movement Disorder Society
555 East Wells Street, Suite 1100
Milwaukee, WI 53202-3823 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
E-mail: info@movementdisorders.org
Website: www.movementdisorders.org
INTERNATIONAL CONGRESS INFORMATION

Dates
Sunday, June 17 through Thursday, June 21, 2012

Official Language
The official language of the International Congress is English.

Venue
The Convention Centre Dublin
Spencer Dock, North Wall Quay
Dublin 1
Ireland

Exhibition
Manufacturers, distributors and suppliers of products and services for physicians and researchers involved with Movement Disorders are invited to participate in the International Congress exhibition. To receive a copy of the Exhibitor Prospectus, please contact the MDS International Secretariat at congress@movementdisorders.org or visit the International Congress section of the MDS website. The exhibition is open to all registered delegates.

Abstract Poster Sessions
Poster Sessions will be featured each day during the International Congress to ensure delegates are given the opportunity to review as many abstracts as possible. Please visit www.mdscongress2012.org/ for a detailed poster schedule, including information about the Guided Poster Tours.

Registration
Visit www.mdscongress2012.org/registration/ to register online.

Fees (in USD):

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>MDS Member</td>
<td>$550</td>
<td>$600</td>
<td>$650</td>
</tr>
<tr>
<td>Non-member</td>
<td>$750</td>
<td>$800</td>
<td>$850</td>
</tr>
<tr>
<td>Junior member/participant*</td>
<td>$300</td>
<td>$325</td>
<td>$350</td>
</tr>
<tr>
<td>Health Professional</td>
<td>$300</td>
<td>$325</td>
<td>$350</td>
</tr>
</tbody>
</table>

The International Congress registration fee includes admission to all scientific sessions, Exhibit Hall, Poster Areas, Welcome Ceremony, MDS Video Games and a meeting bag and documentation. Admission excludes guests and hotel accommodations.

*Participants born after January 1, 1982 (copy of official document required- please submit with registration form, without this document, the delegate will be charged the non-member rate)

Registration Confirmation
Attendees who register online will receive a confirmation message immediately. Please present this confirmation at the International Congress registration desk in Dublin in order to receive your registration materials.

Cancellation/Refund Policy
All cancellations must be requested in writing.
Up to May 30: (final pre-registration deadline) 100% refund, minus a $75 administrative charge
From May 31 – June 11: 50% refund
From June 12 onward: no refund

Group Registration
Companies registering groups of six or more individuals should contact the MDS Registration Bureau by completing a group registration form online: www.mdscongress2012.org/registration/group. A username and password will be sent within a day or two to allow you to manage your own group.

Scientific Sessions
The 2012 Scientific Program will incorporate Therapeutic Plenary Sessions, Plenary and Parallel Sessions, Teaching Courses, Video Sessions, Skills Workshops, Guided Poster Tours and Blue Ribbon Highlights.

Sessions will focus on the latest developments in:
• Genetics in Movement Disorders
• Movement Disorder topics, including, but not limited to, ataxia, chorea, dystonia, myoclonus, Parkinson’s disease, restless legs syndrome, spasticity, stereotypes, tics and tremors
• Basic Science issues, including, but not limited to, genetics, neuroimaging, neuropharmacology, surgical therapy and transplantation
• Other less common clinical conditions
INTERNATIONAL CONGRESS INFORMATION

Special Accessibility Needs
Delegates requiring special arrangements in order to fully participate in the International Congress should provide a written description of such needs on their registration form or send an e-mail to congress@movementdisorders.org. To ensure appropriate accommodations, all special needs should be addressed in advance with the MDS International Secretariat.

Camera Policy
Cameras are not permitted in any 16th International Congress educational sessions or in the poster areas.

Weather
The average daytime temperature in Dublin in June is about 57° F (14° C).

Currency
The exchange rate for US Dollars as of January 27, 2012 is: 1 USD = 0.75 Euro

Estimated Flight Times to Dublin, Ireland

<table>
<thead>
<tr>
<th>From Africa</th>
<th>From Europe</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cairo – 10 hours</td>
<td>Amsterdam – 2 hours</td>
</tr>
<tr>
<td>Johannesberg – 16 hours</td>
<td>Barcelona – 4 hours</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>From Asia</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Bangkok – 18 hours</td>
<td>Istanbul – 6 hours</td>
</tr>
<tr>
<td>Beijing – 15 hours</td>
<td>London – 2 hours</td>
</tr>
<tr>
<td>Hong Kong – 18 hours</td>
<td>Moscow – 7 hours</td>
</tr>
<tr>
<td>Kuala Lumpur – 18 hours</td>
<td>Paris – 2 hours</td>
</tr>
<tr>
<td>New Delhi – 14 hours</td>
<td>Rome – 5 hours</td>
</tr>
<tr>
<td>Seoul – 18 hours</td>
<td>From South America</td>
</tr>
<tr>
<td>Shanghai – 17 hours</td>
<td>Bogota – 16 hours</td>
</tr>
<tr>
<td>Singapore – 18 hours</td>
<td>Buenos Aires - 19 hours</td>
</tr>
<tr>
<td>Tokyo – 17 hours</td>
<td>Sao Paulo – 16 hours</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>From Canada</th>
<th>From USA</th>
</tr>
</thead>
<tbody>
<tr>
<td>Halifax – 12 hours</td>
<td>Chicago – 10 hours</td>
</tr>
<tr>
<td>Toronto – 12 hours</td>
<td>Los Angeles – 15 hours</td>
</tr>
<tr>
<td>Vancouver – 14 hours</td>
<td>Miami – 12 hours</td>
</tr>
<tr>
<td>Winnipeg – 16 hours</td>
<td>New York – 7 hours</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>From Oceania</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Auckland – 31 hours</td>
<td></td>
</tr>
<tr>
<td>Sydney – 27 hours</td>
<td></td>
</tr>
</tbody>
</table>

Events
Welcome Ceremony
Sunday, June 17, 2012
19:00 – 21:00
All International Congress attendees are warmly invited to meet friends and colleagues during the traditional International Congress Welcome Ceremony at The Convention Centre Dublin. This event is open to all registered delegates. Guests are able to purchase a Welcome Ceremony Pass that will allow them admission to this event. Please see below for more information on the Welcome Ceremony Pass.

Welcome Ceremony Pass
Participants who wish to bring an accompanying guest to the Welcome Ceremony may purchase a Welcome Ceremony Pass for $40 USD as part of their registration process. This Pass can only be used during the evening of the Welcome Ceremony on Sunday, June 17, 2012.

MDS Video Games
Wednesday, June 20, 2012
19:00 – 23:00
Please join Masters of Ceremony Anthony Lang and Kapil Sethi as they host a world-renowned panel of Movement Disorders experts in guiding participants through unique Movement Disorder cases.

The cases will be presented by representatives from Movement Disorder Centers around the world and discussed by the two teams of Experts. Awards will be given for the most interesting and challenging cases and the teams of Experts will compete for the highest number of correct diagnoses that they make. Country pride will add an enjoyable spirit of competition to this event.

The goal of this session is for attendees to learn from a series of unusual, very interesting patients and see how senior experts approach these types of challenging cases.

The two teams of Experts are:
TEAM 1:
Alberto Espay, Cincinnatti, OH, USA
Daniel Healy, Dublin, Ireland
Christine Klein, Lübeck, Germany
Marcelo Merello, Buenos Aires, Argentina

VS.
TEAM 2:
Bastiaan Bloem, Nijmegen, Netherlands
Hubert Fernandez, Cleveland, OH, USA
Thomas Warner, London, United Kingdom
Ruey-Meei Wu, Taipei, Taiwan

Following the International Congress, the cases presented could be developed further for publication in the Journal or presentation on the Society’s website. This social event is open to all registered delegates. For more information about the MDS Video Games, please contact Sarah Smith at ssmith@movementdisorders.org.
CME INFORMATION

Purpose
The purpose of the MDS International Congress is to offer a forum for clinical and basic discussion on a variety of Movement Disorder topics, including presentations of current research and available treatments.

Learning Objectives
Through state-of-the-art lectures, hot topic reviews, controversy debates, teaching courses, skills workshops and video sessions, participants will be better able to:
1. Describe the pathophysiology and neurobiology of Parkinson’s disease and other movement disorders;
2. Discuss the diagnostic approaches and tools available for Parkinson’s disease and other movement disorders;
3. Discuss the pharmacological and non-pharmacological treatment options available for Parkinson’s disease and other movement disorders.

Continuing Medical Education
The Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Accreditation Statement
The Movement Disorder Society designates this live activity for a maximum of 35.0 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

The Movement Disorder Society has sought accreditation from the European Accreditation Council for Continuing Medical Education (EACCME) to provide CME credits for medical specialists.

The EACCME is an institution of the European Union of Medical Specialists (UEMS). For more information, visit www.uems.net.

Target Audience
The target audience of the 16th International Congress of Parkinson’s Disease and Movement Disorders includes clinicians, researchers, post-doctoral fellows, medical residents, medical students and other healthcare professionals with an interest in the current research and approaches for the diagnosis and treatment of movement disorders.

Faculty Financial Disclosure Information
It is the policy of The Movement Disorder Society (MDS) to ensure balance, independence, objectivity and scientific rigor in all sponsored educational activities. All faculty participating in any MDS sponsored activities are required to disclose to the activity audience any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the Continuing Medical Education (CME) activity. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is not to prevent a speaker with a potential conflict of interest from making a presentation. It is merely intended that any potential conflict should be identified openly so that the listeners may form their own judgments about the presentation with the full disclosure of the facts. It remains for the audience to determine whether the speaker’s outside interest may reflect a possible bias in either the exposition or the conclusions presented.

Faculty financial disclosure information will be provided to participants onsite in Dublin.
# PROGRAM-AT-A-GLANCE

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>7:00</td>
<td>Committee Meetings 7:00 - 8:00</td>
<td>Committee Meetings 7:00 - 8:00</td>
<td>Committee Meetings 7:00 - 8:00</td>
<td>Committee Meetings 7:00 - 8:00</td>
<td>Committee Meetings 7:00 - 8:00</td>
</tr>
<tr>
<td>7:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:00</td>
<td>Therapeutic Plenary Session I 8:00 - 10:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>Break 10:00 - 10:30</td>
<td>Break 10:00 - 10:45</td>
<td>Break 10:00 - 10:45</td>
<td>Break 10:00 - 10:30</td>
<td>Break 10:00 - 10:30</td>
</tr>
<tr>
<td>10:30</td>
<td>Therapeutic Plenary Session II 10:30 - 12:30</td>
<td>Plenary Session VI 10:45 - 12:45</td>
<td>Plenary Session VIII 10:45 - 12:15</td>
<td>Plenary Session X 10:30 - 12:00</td>
<td>Blue Ribbon Highlights 11:00 - 12:00</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Break/ Guided Poster Tours/ Poster Sessions 12:00 - 13:30</td>
</tr>
<tr>
<td>11:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:30</td>
<td>Break 12:30 - 14:00</td>
<td></td>
<td></td>
<td></td>
<td>Break/ Guided Poster Tours/ Poster Sessions 12:00 - 13:30</td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>Therapeutic Plenary Session III 14:00 - 16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>Break 16:00 - 16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>Therapeutic Plenary Session IV 16:30 - 18:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:30</td>
<td>Break 18:30 - 19:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>Welcome Ceremony 19:00 - 21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>21:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>23:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
MDS 16TH INTERNATIONAL CONGRESS SESSION DEFINITIONS

**Blue Ribbon Session:**
This session will provide a critical review of the best poster presentations by a panel of experts, highlighting the relevance, novelty and quality of both clinical and basic research presented by the delegates.

**Controversies:**
This Plenary Session is designed to involve all International Congress attendees. Content is prepared to stimulate interest and debate among a panel of experts. Views from several angles will be addressed as discussion of pre-selected “hot” topics will be open for debate among the panelists.

**Corporate Therapeutic Symposia:**
These company-based informational sessions will provide attendees with non-CME educational opportunities to learn the latest in therapeutics.

**Guided Poster Tours:**
Guided Poster Tours will give small groups of delegates an opportunity to hear discussion on a select group of abstracts in several sub-categories.

Delegates interested in attending a Guided Poster Tour may sign up and receive a tour ticket at the MDS Desk beginning Sunday, June 17. Attendance is limited, and tickets will be given on a first-come, first-served basis. Delegates are encouraged to sign up early to ensure availability.

There will be four simultaneous tours per day from Monday, June 18 through Thursday, June 21.

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, June 18</td>
<td>12:45 – 14:15</td>
</tr>
<tr>
<td>Tuesday, June 19</td>
<td>12:15 – 13:45</td>
</tr>
<tr>
<td>Wednesday, June 20</td>
<td>12:00 – 13:30</td>
</tr>
<tr>
<td>Thursday, June 21</td>
<td>12:00 – 13:30</td>
</tr>
</tbody>
</table>

A complete schedule with specific topic dates and times will be available soon.

**Parallel Sessions:**
These concurrent sessions provide an in-depth report of the latest research findings, state-of-the-art treatment options, as well as a discussion of future strategies. Parallel sessions will have evidence-based components and incorporate the “hot” issues in Parkinson’s disease and other movement disorders.

**Plenary Sessions:**
These sessions provide a broad overview of the latest clinical and basic science research findings and state-of-the-art information.

**Poster Sessions:**
Poster sessions give each delegate an opportunity to view their colleagues’ posters on the most current research in the field of Movement Disorders. Authors will be present for 1.5 hours each day to explain their work and answer questions.

**Skills Workshops:**
These clinic-based training sessions provide an educational illustration of clinical techniques and treatment procedures through demonstrations utilizing patient videotapes and proper equipment to further develop practitioners’ skills and knowledge within the field of treatment of movement disorders.

**Teaching Courses:**
These educational programs provide up-to-date information focused on a single topic. The sessions highlight both the clinical and basic science of topics of relevance to Movement Disorder specialists. The sessions are unique in providing a syllabus that includes a review of the topic and the presentation slides. In addition, these programs provide ample time for questions and a discussion period at the conclusion of the presentations.

**Therapeutic Plenary Sessions:**
These sessions provide the latest information regarding the scientific and clinical evidence supporting treatment options for Parkinson’s disease and other movement disorders.

**Video Sessions:**
Designed to provide a broad overview of related movement disorders, the video sessions will focus on the phenomenology covering the many different kinds of movement disorders affecting the population today.

**SPECIAL MEETING THEME:**
The perils and promises of genetics in movement disorders

At each annual International Congress, the Congress Scientific Program Committee selects a theme that is highlighted throughout the meeting. This year’s theme, “The perils and promises of genetics in movement disorders,” will be showcased in two Plenary Sessions, five Parallel Sessions, three Skills Workshops, two Video Sessions, and one Teaching Course. International experts will serve as faculty, and the presentations will run the gamut of the field, from new research to practical applications. Meeting participants can elect to attend any or all of the sessions.

These sessions are designated with a 🍀.
SUNDAY, JUNE 17, 2012

1105 Therapeutic Plenary Session I
Novel neuropharmacological approaches to treating Parkinson’s disease: Hope or hype?
8:00 - 10:00
Chairs: Olivier Rascol
Toulouse, France
Michael Schwarzschild
Sharon, MA, USA
8:00 How to deliver the promise of neurotrophic factors in Parkinson’s disease
C. Warren Olanow
New York, NY, USA
8:40 Making dopamine treatments better: Still flogging a dead horse?
Donald Grosset
Glasgow, United Kingdom
9:20 Novel non-dopaminergic targets for the motor symptoms of Parkinson’s disease
Michael Schwarzschild
Sharon, MA, USA
At the conclusion of this session, participants should be better able to:
1. Understand issues related to the use and delivery of neurotrophic factors as possible therapeutic options for Parkinson’s disease
2. Describe novel dopaminergic agents in development and new delivery systems for levodopa/apomorphine
3. Outline the rationale for non-dopaminergic strategies in development for the motor symptoms of Parkinson’s disease
Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

1106 Therapeutic Plenary Session II
Recent developments in Deep Brain Stimulation
10:30 – 12:30
Chairs: Philip Starr
San Francisco, CA, USA
Lars Timmermann
Cologne, Germany
10:30 Target choice in Parkinson’s disease: GPI or STN?
Ken Follett
Omaha, NE, USA
11:10 Deep Brain Stimulation for cognitive enhancement
Emad Eskandar
Boston, MA, USA
11:50 Closed-loop stimulation in Parkinson’s disease
Lars Timmermann
Cologne, Germany
At the conclusion of this session, participants should be better able to:
1. Describe relative indications for DBS of STN versus GPI in Parkinson’s disease
2. Understand basis for contingent (closed loop) stimulation in Parkinson’s disease
3. Assess potential basis for improving human cognition using DBS
Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees
Supported by an unrestricted educational grant from Medtronic.

1107 Therapeutic Plenary Session III
Treatment of the psychiatric and cognitive disorders of Parkinson’s disease: Evidence or expertise?
14:00 – 16:00
Chairs: Daniel Weintraub
Ardmore, PA, USA
Laura Marsh
Houston, TX, USA
14:00 Treatment of dementia and mild cognitive impairment in Parkinson’s disease: Do drugs really work?
Jaime Kulisevsky
Barcelona, Spain
14:40 Treatment of affective disorders in Parkinson’s disease: How do I choose which drug to use?
Laura Marsh
Houston, TX, USA
15:20 Treatment of psychosis and behavioral disorders in Parkinson’s disease: Help or hindrance?
Daniel Weintraub
Ardmore, PA, USA
At the conclusion of this session, participants should be better able to:
1. Summarize recent clinical trials for psychiatric and cognitive disorders in Parkinson’s disease
2. Critically evaluate the relative benefits and risks of various treatment strategies for common neuropsychiatric symptoms in Parkinson’s disease
3. Assess benefit vs. tolerability of common psychiatric and cognitive treatments in Parkinson’s disease
Recommended Audience: Basic scientists, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

1108 Therapeutic Plenary Session IV
The practical application of evidence-based medicine in Parkinson’s disease
16:30 – 18:30
Chairs: Timothy Counihan
Galway, Ireland
Klaus Seppi
Innsbruck, Austria
16:30 Neuroprotection and early symptomatic treatment
Shen-Yang Lim
Kuala Lumpur, Malaysia
17:10 Later motor problems
Regina Katzenschlager
Vienna, Austria
17:50 Non-motor features: Beyond neuropsychiatric
Klaus Seppi
Innsbruck, Austria
At the conclusion of this session, participants should be better able to:
1. Understand the status of neuroprotective/disease modifying therapy in Parkinson’s disease
2. Recognize the pros and cons related to the available treatments for the motor symptoms of Parkinson’s disease
3. Apply treatments shown to be of benefit for the non-cognitive, non-neuropsychiatric non-motor features of Parkinson’s disease
Recommended Audience: Clinical academicians, Health Professionals (Non-Physician), Students/Residents/Trainees, Practitioners

Welcome Ceremony
19:00 – 21:00
MONDAY, JUNE 18, 2012

2103 Plenary Session V
Is it time to change how we define Parkinson’s disease?
8:00 – 10:00
Chairs: Anthony Lang
Toronto, ON, Canada
Matthew Stern
Philadelphia, PA, USA
8:00 A clinical diagnosis based on bradykinesia, tremor and rigidity: Pathology and genetics are irrelevant
Bastiaan Bloem
Nijmegen, Netherlands
8:40 Parkinson’s disease is a synucleinopathy: The clinical syndrome and genetics are irrelevant
Glenda Halliday
Randwick, Australia
9:20 Parkinson’s disease is a genetic disorder and should be defined as such: The clinical syndrome and pathology are irrelevant
Matthew Farrer
Vancouver, BC, Canada
At the conclusion of this session, participants should be better able to:
1. Describe the different pathological changes associated with genetic Parkinson’s disease
2. Identify the clinical features associated with Lewy body pathology
3. Recognize the various genetic factors that are associated with Parkinson’s disease
Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

2104 Plenary Session VI, cont.
12:05 Newer clinical trial designs for future therapeutic studies
Bernard Ravina
Cambridge, MA, USA
At the conclusion of this session, participants should be better able to:
1. Understand the need to re-engineer the translational process and the options that modern technologies provide
2. Understand the challenges to standard animal models and the potential for new models of efficacy testing
3. Recognize the potential and need for new clinical trial designs including adaptive trial designs, new approaches to patient stratification, etc.
Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

2104 Plenary Session VI
Revising translational research approaches in neurodegeneration
10:45 – 12:45
Chairs: Virginia Lee
Philadelphia, PA, USA
John Trojanowski
Philadelphia, PA, USA
10:45 Re-engineering translational sciences: New approaches to the development of diagnostics and therapeutics in neurodegenerative diseases
John Trojanowski
Philadelphia, PA, USA
11:25 Pre-clinical efficacy testing: The future role of animal vs. newer efficacy models
Virginia Lee
Philadelphia, PA, USA

2207 Parallel Session
Whatever happened to environmental factors in the etiology of Parkinson’s disease? Are they still important?
15:45 – 17:45
Chairs: Francesca Cicchetti
Quebec, PQ, Canada
Riona Mulcahy
Waterford, Ireland
16:25 Environmental factors: What have we learned from animal models?
Alberto Ascherio
Boston, MA, USA
17:05 Epigenetics of psychiatric and neurological diseases
Art Petronis
Toronto, ON, Canada
At the conclusion of this session, participants should be better able to:
1. Describe the role of environmental factors and toxins in causing parkinsonism
2. Understand how animal models inform our understanding of the pathophysiology of Parkinson’s disease
3. Explain epigenetic mechanisms and their possible relevance to the pathogenesis of Parkinson’s disease
Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees

Supported by an unrestricted educational grant from Elan Pharmaceuticals, Inc.
MONDAY, JUNE 18, 2012

2208 Parallel Session
Gait and postural control in movement disorders: New perspectives
15:45 – 17:45
Chairs: Fay Horak
Portland, OR, USA
Lynn Rochester
Newcastle upon Tyne, United Kingdom
15:45 Imaging gait and postural control: Methods, mechanisms and pathology
Ivan Toni
Nijmegen, Netherlands
16:25 Gait and postural control as biomarkers of Parkinson's disease progression
Fay Horak
Portland, OR, USA
17:05 Non-dopaminergic contribution to gait and postural dysfunction in Parkinson's disease and its therapeutic implications
Nicolaas Bohnen
Saline, MI, USA

At the conclusion of this session, participants should be better able to:
1. Understand developments in neuroimaging gait and postural control, limitations and neural correlates
2. Identify the role of gait and postural control in predicting outcome in movement disorders
3. Understand the role of non-dopaminergic pathology in gait and postural control and alternative therapeutic approaches

Recommended Audience: Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

2209 Parallel Session, cont.
Infectious diseases, autoimmunity and movement disorders
15:45 – 17:45
Chairs: Russell Dale
Sydney, Australia
Sean O’Riordan
Dublin, Ireland
15:45 The spectrum of Streptococcal-related movement disorders
Davide Martino
Bari, Italy
16:25 Post-encephalitic movement disorders
Usha Misra
Lucknow, India
17:05 Autoimmune mediated movement disorders
Russell Dale
Sydney, Australia

At the conclusion of this session, participants should be better able to:
1. Identify movement disorders associated with infectious and autoimmune diseases
2. Describe infectious and autoimmune mechanisms causing movement disorders in infectious diseases
3. Discuss the prevention and treatment of movement disorders associated with infections or autoimmunity

Recommended Audience: Basic Scientists, Clinical academicians, Practitioners

2208 Teaching Course
Update on psychogenic movement disorders
15:45 – 17:45
Chairs: Mark Hallett
Bethesda, MD, USA
Jon Stone
Edinburgh, United Kingdom

At the conclusion of this session, participants should be better able to:
1. Describe the major features for Parkinson’s disease compared to red flags for atypical parkinsonism
2. Determine essential diagnostic procedures and how meaningful they are
3. Manage the start of treatment of Parkinson’s disease

Recommended Audience: Clinical academicians, Students/Residents/Trainees, Practitioners
**MONDAY, JUNE 18, 2012**

**2403 Skills Workshop**

Is my movement disorder genetic and what does that mean for me and my family?

**18:15 – 19:45**

In this interactive session, the faculty will present clinical cases from their own practice and discuss the lessons learned when critical reappraisal of clinical features has led to a revision of diagnosis and change in management.

**Philip Thompson**

Adelaide, Australia

**Eduardo Tolosa**

Barcelona, Spain

At the conclusion of this session, participants should be better able to:
1. Describe how to take a detailed family history and draw an appropriate pedigree
2. Interpret pedigrees with respect to different possible modes of inheritance
3. Appreciate the important ethical issues and principles involved in genetic counseling

**Recommended Audience:** Clinical academicians, Practitioners, Students/Residents/Trainees

**2404 Skills Workshop**

Lessons I learned from my patients

**18:15 – 19:45**

In this interactive session, the faculty will critically review cases where diagnostic or management revisions were made.

**At the conclusion of this session, participants should be better able to:**
1. Recognize potential behavioral problems associated with therapy
2. Discuss strategies to management of behavioral problems
3. Identify how and when to discuss behavioral problems with patient and family

**Recommended Audience:** Clinical academicians, Practitioners, Students/Residents/Trainees

**2405 Skills Workshop**

The role of the nurse in the management of behavioral problems in movement disorders

**18:15 – 19:45**

In this interactive session, the faculty will review the role of the movement disorder nurse in identifying complex behavioral problems, discuss the limitations of current therapy and the implications and alternatives for therapeutic management of symptoms.

**Stephen Smith**

Norfolk, United Kingdom

**Brian Magennis**

Dublin, Ireland

At the conclusion of this session, participants should be better able to:
1. Recognize the lessons for clinical practice from
2. Identify frequent and preventable pitfalls in the evaluation of movement disorders patients
3. Recognize the merits of periodic reassessment of clinical features and patient’s management

**Recommended Audience:** Clinical academicians, Practitioners, Students/Residents/Trainees

**2406 Skills Workshop**

Getting the best out of botulinum toxin treatment

**18:15 – 19:45**

In this interactive session, the faculty will review the best approach to evaluate patients requiring botulinum toxin injections, how to deploy clinical strategies to manage such patients, and the best techniques to administer botulinum toxin.

**A. Peter Moore**

Liverpool, United Kingdom

**Erie Chuen-Hian Lim**

Singapore

At the conclusion of this session, participants should be better able to:
1. Develop an approach to evaluate patients for botulinum toxin treatment
2. Deploy effective clinical strategies for dealing with both challenging and apparently straightforward cases
3. Understand the basis for guidance techniques in botulinum toxin injections compared to surface marking

**Recommended Audience:** Clinical academicians, Practitioners, Students/Residents/Trainees

**2407 Skills Workshop**

How to distinguish Parkinson’s disease subtypes

**18:15 – 19:45**

In this interactive session, the faculty will be instructed on using clinical and investigational tools to identify different subtypes of Parkinson’s disease. The latest research and thinking in this area will be highlighted.

**Bob Van Hilten**

Leiden, Netherlands

**Ryan Uitti**

Jacksonville, FL, USA

At the conclusion of this session, participants should be better able to:
1. Describe different subtypes of Parkinson’s disease
2. Discuss the clinical and prognostic significance of such subtyping
3. Identify future research trends in this area using the latest tools available

**Recommended Audience:** Basic scientists, Clinical academicians, Practitioners

**2408 Skills Workshop**

Movement disorders emergencies

**18:15 – 19:45**

In this interactive session, problematic movement disorder emergencies will be discussed. This session will include unusual presentations of known conditions that may be treatable and present with disorders of movement.

**Marco Onofrj**

Pescara, Italy

**Helio Teive**

Curitiba, Brazil

At the conclusion of this session, participants should be better able to:
1. Develop an understanding of motor emergencies that occur in parkinsonism, including severe rigidity and hyperpyrexia
2. Identify and learn to manage acute and/or severe movement disorder complications from DBS and other neurosurgical procedures
3. Recognize the unusual presentation of rare and often treatable movement disorders

**Recommended Audience:** Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

Supported by an unrestricted educational grant from Ipsen.
MONDAY, JUNE 18, 2012

2509 Video Session

Drug-induced movement disorders
18:15 – 19:45
In this interactive session, which will be well-illustrated with video examples, the clinical characteristics and management of movement disorders caused by drug therapy will be discussed as well as the classification and identification of the pharmaceutical agents that can lead to these iatrogenic syndromes.

Joseph Friedman
Barrington, RI, USA

Daniel Tarsy
Boston, MA, USA

At the conclusion of this session, participants should be better able to:
1. Recognize and treat acute drug-induced movement disorders including parkinsonism, acute dystonic reaction, akathisia and neuroleptic malignant syndrome
2. Understand the pathogenesis, phenomenology, natural history and management of the tardive syndromes
3. Appreciate the range of drugs, in addition to typical antipsychotic agents, that can be responsible for inducing movement disorders

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

TUESDAY, JUNE 19, 2012

3103 Plenary Session VII

Lost in translation: Has genetics informed our knowledge of non-parkinsonian movement disorders?
8:00 – 10:00

Chairs: Michael Hutchinson
Dublin, Ireland
Christine Klein
Lübeck, Germany

8:00 What is more important: DYT phenotype or genotype?
Christine Klein
Lübeck, Germany

8:40 Getting the balance right: Can we make sense of the SCAs?
Bart van de Warrenburg
Nijmegen, Netherlands

9:20 Has identification of the Huntington’s disease gene mutation been the most over-hyped scientific news in the last twenty years?
M. Flint Beal
New York, NY, USA

3104 Plenary Session VIII

Recent and ongoing clinical trials in movement disorders
10:45 – 12:15

Chairs: Joseph Jankovic
Houston, TX, USA
Werner Poewe
Innsbruck, Austria

10:45 Clinical trials in Parkinson’s disease
Werner Poewe
Innsbruck, Austria

11:15 Clinical trials in other movement disorders
Joaquim Ferreira
Lisbon, Portugal

11:45 Clinical trials in DBS surgery
Günther Deuschl
Kiel, Germany

At the conclusion of this session, participants should be better able to:
1. Critically assess the most important recent clinical trials in Parkinson’s disease and other movement disorders
2. Integrate clinical trials results into clinical practice
3. List unmet therapeutic needs which require further studies

Recommended Audience: Basic scientists, Health Professionals (Non-Physician), Students/Residents/Trainees

3207 Parallel Session

Is Parkinson’s disease a mitochondrial or proteostatic disorder?
15:15 – 17:15

Chairs: Gavin Davey
Dublin, Ireland
D. James Surmeier
Chicago, IL, USA

15:15 Oxidative stress and mitochondrial dysfunction in Parkinson’s disease
D. James Surmeier
Chicago, IL, USA

At the conclusion of this session, participants should be better able to:
1. Describe functional imaging changes underlying preclinical Parkinson’s disease and asymptomatic carriers
2. Identify abnormal connectivity and receptor changes in hereditary movement disorders
3. Explain how dopaminergic gene polymorphisms influence neural networks affecting behavior and cognition in Parkinson’s disease

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees
**TUESDAY, JUNE 19, 2012**

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Type</th>
<th>Title</th>
<th>Chairs</th>
<th>Date/Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>3209</td>
<td>Parallel Session</td>
<td>Update on DBS in hyperkinetic movement disorders</td>
<td>Paul Krack, Jens Volkmann</td>
<td>15:15 – 17:15</td>
</tr>
<tr>
<td>3210</td>
<td>Parallel Session</td>
<td>What is new in PSP?</td>
<td>Irene Litvan, Günter Höglinger</td>
<td>15:15 – 17:15</td>
</tr>
<tr>
<td>3211</td>
<td>Parallel Session</td>
<td>Etiopathogenesis of PSP: Genetics</td>
<td>Günter Höglinger, Munich, Germany</td>
<td>15:15</td>
</tr>
<tr>
<td>3212</td>
<td>Parallel Session</td>
<td>Etiopathogenesis of PSP: Occupation and Environment</td>
<td>Irene Litvan, La Jolla, CA, USA</td>
<td>15:55</td>
</tr>
<tr>
<td>3213</td>
<td>Parallel Session</td>
<td>Treatment of PSP and other tauopathies</td>
<td>Adam Boxer, San Francisco, CA, USA</td>
<td>16:35</td>
</tr>
<tr>
<td>3309</td>
<td>Teaching Course</td>
<td>Frontotemporal dementias and parkinsonism</td>
<td>Hugh Harrington, Ian Mackenzie</td>
<td>15:15 – 17:15</td>
</tr>
<tr>
<td>3310</td>
<td>Teaching Course</td>
<td>Update on levodopa-induced dyskinesias</td>
<td>Giovanni Fabbri, Susan Fox</td>
<td>15:15 – 17:15</td>
</tr>
<tr>
<td>3311</td>
<td>Teaching Course</td>
<td>Preventative and management strategies for levodopa-induced dyskinesias</td>
<td>Federico Micheli, Buenos Aires, Argentina</td>
<td>15:15 – 17:15</td>
</tr>
<tr>
<td>3312</td>
<td>Teaching Course</td>
<td>Phenomenology, classification and assessment of levodopa-induced dyskinesias</td>
<td>Giovanni Fabbri, Rome, Italy</td>
<td>15:15 – 17:15</td>
</tr>
</tbody>
</table>

**Recommended Audience:**
- Basic scientists
- Clinical academicians
- Practitioners
- Students/Residents/Trainees

**Chairs:**
- Paul Krack, Grenoble, France
- Jens Volkmann, Würzburg, Germany
- Günter Höglinger, Munich, Germany
- Irene Litvan, La Jolla, CA, USA
- Adam Boxer, San Francisco, CA, USA
- Hugh Harrington, Cork, Ireland
- Ian Mackenzie, Vancouver, BC, Canada
- Giovanni Fabbri, Rome, Italy
- Susan Fox, Toronto, ON, Canada
- Victor Fung, Sydney, Australia

**Session Descriptions**

- **Update on DBS in hyperkinetic movement disorders**
  - **Chairs:** Paul Krack, Jens Volkmann
  - **Date/Time:** 15:15 – 17:15
  - **Description:** Update on deep brain stimulation (DBS) in hyperkinetic movement disorders.

- **What is new in PSP?**
  - **Chairs:** Irene Litvan, Günter Höglinger
  - **Date/Time:** 15:15 – 17:15
  - **Description:** Discussion on recent advances in the pathology of progressive supranuclear palsy (PSP).

- **Etiopathogenesis of PSP: Genetics**
  - **Chairs:** Günter Höglinger, Munich, Germany
  - **Date/Time:** 15:15
  - **Description:** Exploration of genetic factors in the etiopathogenesis of PSP.

- **Etiopathogenesis of PSP: Occupation and Environment**
  - **Chairs:** Irene Litvan, La Jolla, CA, USA
  - **Date/Time:** 15:55
  - **Description:** Examination of environmental and occupational factors in PSP.

- **Treatment of PSP and other tauopathies**
  - **Chairs:** Adam Boxer, San Francisco, CA, USA
  - **Date/Time:** 16:35
  - **Description:** Strategies for the treatment of PSP and other tauopathies.

- **Frontotemporal dementias and parkinsonism**
  - **Chairs:** Hugh Harrington, Ian Mackenzie
  - **Date/Time:** 15:15 – 17:15
  - **Description:** Discussion on the latest advances in the management of frontotemporal dementias and parkinsonism.

- **Update on levodopa-induced dyskinesias**
  - **Chairs:** Giovanni Fabbri, Susan Fox
  - **Date/Time:** 15:15 – 17:15
  - **Description:** Update on management strategies for levodopa-induced dyskinesias.

- **Preventative and management strategies for levodopa-induced dyskinesias**
  - **Chairs:** Federico Micheli, Giovanni Fabbri
  - **Date/Time:** 15:15 – 17:15
  - **Description:** Strategies for preventing and managing levodopa-induced dyskinesias.
### TUESDAY, JUNE 19, 2012

<table>
<thead>
<tr>
<th>Session Code</th>
<th>Type</th>
<th>Title</th>
<th>Time</th>
<th>Location</th>
<th>Speakers</th>
<th>Audience</th>
</tr>
</thead>
<tbody>
<tr>
<td>3404</td>
<td>Skills Workshop</td>
<td>How to critically read and interpret genetic and molecular biological literature in movement disorders (e.g., GWAS studies)</td>
<td>17:45 – 19:15</td>
<td>Madrid, Spain</td>
<td>Vincenzo Bonifati, Rotterdam, Netherlands</td>
<td>Basic scientists, Clinical academicians, Students/Residents/Trainees</td>
</tr>
<tr>
<td>3406</td>
<td>Skills Workshop</td>
<td>Modern concepts of palliative care and end of life issues in parkinsonism</td>
<td>17:45 – 19:15</td>
<td>Jerusalem, Israel</td>
<td>Mark Lee, Sunderland, United Kingdom</td>
<td>Students/Residents/Trainees, Practitioners, Health Professionals (Non-Physician)</td>
</tr>
<tr>
<td>3407</td>
<td>Skills Workshop</td>
<td>Multidisciplinary care for Parkinson’s disease: Why, who, and when?</td>
<td>17:45 – 19:15</td>
<td>Rotterdam, Netherlands</td>
<td>Marcelo Merello, Buenos Aires, Argentina</td>
<td>Students/Residents/Trainees, Practitioners, Health Professionals (Non-Physician)</td>
</tr>
<tr>
<td>3508</td>
<td>Video Session</td>
<td>Clinical clues and pearls in the recognition of the primary dystonias and dystonia-plus syndromes: Genotype-Phenotype correlation</td>
<td>17:45 – 19:15</td>
<td>Miami, FL, USA</td>
<td>Janis Miyasaki, Miami, FL, USA</td>
<td>Students/Residents/Trainees, Practitioners, Health Professionals (Non-Physician)</td>
</tr>
<tr>
<td>3509</td>
<td>Video Session</td>
<td>The eyes as a window into the diagnosis of movement disorders</td>
<td>17:45 – 19:15</td>
<td>Miami, FL, USA</td>
<td>Janet Rucker, Miami, FL, USA</td>
<td>Students/Residents/Trainees, Practitioners, Health Professionals (Non-Physician)</td>
</tr>
</tbody>
</table>

**Support:** Supported by an unrestricted educational grant from Ipsen.
TUESDAY, JUNE 19, 2012

3510 Video Session

Unusual movement disorders: A potpourri
17:45 – 19:15
In this interactive session, the faculty will show a variety of rare and unusual hypokinetic and hyperkinetic movement disorders. An organized approach to the differential diagnosis will be discussed. Audience participation is encouraged and they may bring unusual cases for presentation.
Alberto Espay
Cincinnati, OH, USA
Kailash Bhatia
London, United Kingdom

At the conclusion of this session, participants should be better able to:
1. Identify rare hypokinetic movement disorders and differentiate these from the common varieties
2. Discuss unusual hyperkinetic movement disorders
3. Describe an approach to the differential diagnosis of unusual movement disorders

Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

WEDNESDAY, JUNE 20, 2012

4103 Plenary Session IX

Presidential Lectures
8:00 – 10:00
Chairs: Günther Deuschl
Kiel, Germany
Matthew Stern
Philadelphia, PA, USA
8:00 Stanley Fahn Lecture: The Edgelands of the Shaking Palsy
Andrew Lees
London, United Kingdom
8:30 Junior Award Lecture: Clinical Science
To be announced
9:00 Junior Award Lecture: Basic Science
To be announced
9:30 C. David Marsden Lecture: Using genetic analysis to get at the biology of Parkinson's disease
John Hardy
London, United Kingdom

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

4104 Plenary Session X

At-risk cohorts for Parkinson’s disease: Where do we stand?
10:30 – 12:00
Chairs: Daniel Healy
Dublin, Ireland
Matthew Stern
Philadelphia, PA, USA
10:30 Markers for pre-manifest Parkinson’s disease
Matthew Stern
Philadelphia, PA, USA
11:00 What are we learning from our pre-manifest Parkinson’s disease cohorts?
Daniela Berg
Tübingen, Germany
11:30 Are we ready to conduct clinical trials in pre-manifest Parkinson’s disease?
Olivier Rascol
Toulouse, France

At the conclusion of this session, participants should be better able to:
1. Understand the challenges of diagnosing pre-manifest Parkinson’s disease and characterize markers according to their predictive value
2. Consider essentials for designing a pre-Parkinson’s disease study
3. Discuss prerequisites to conduct clinical trials in pre-manifest Parkinson’s disease

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

4208 Parallel Session, cont.

What is essential tremor?
15:00 – 17:00
Chairs: Günther Deuschl
Kiel, Germany
Rodger Elble
Springfield, IL, USA
15:00 A clinical perspective
Rodger Elble
Springfield, IL, USA
15:40 A neurophysiological perspective
Alfons Schnitzler
Düsseldorf, Germany
16:20 A biological perspective
Alexander Rajput
Saskatoon, SK, Canada

At the conclusion of this session, participants should be better able to:
1. Identify the controversies related to what constitutes essential tremor and its association with other movement disorders
2. Recognize the genetic heterogeneity of essential tremor and the challenges to defining its genetic basis
3. Discuss the various pathological findings that have been associated with essential tremor and the controversies related to these

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

4209 Parallel Session

Paraneoplastic and other autoimmune movement disorders
15:00 – 17:00
Chairs: Victor Fung
Sydney, Australia
Angela Vincent
Headington, United Kingdom
15:00 Pathogenesis of paraneoplastic syndromes
Angela Vincent
Headington, United Kingdom
15:40 Diagnosis and management of paraneoplastic syndromes which present with a hyperkinetic movement disorder
Thomas Kimber
Adelaide, Australia
16:20 Diagnosis and management of paraneoplastic syndromes which present with stiffness or rigidity
Hans-Michael Meinck
Heidelberg, Germany

At the conclusion of this session, participants should be better able to:
1. Understand the pathogenesis of different paraneoplastic syndromes
2. Describe specific paraneoplastic syndromes which present with movement disorders
3. Describe an approach to the diagnosis and management of paraneoplastic syndromes

Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees
1. Describe representations of movement disorders in visual arts and literature
At the conclusion of this session, participants should be better able to:
1. Understand the principal ways in which sensory input is used to control voluntary movement
2. Describe how demonstrated disorders of sensory processing contribute to symptoms of focal and generalized dystonia
3. Interpret how sensory deficits may contribute to motor disturbances in Parkinson’s disease
Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

16:20 Genetic choreas
Sarah Tabrizi
London, United Kingdom
At the conclusion of this session, participants should be better able to:
1. Understand the principal ways in which sensory input is used to control voluntary movement
2. Describe how demonstrated disorders of sensory processing contribute to symptoms of focal and generalized dystonia
3. Interpret how sensory deficits may contribute to motor disturbances in Parkinson’s disease
Recommended Audience: Clinical academicians, Practitioners, Students/Residents/Trainees

17:00 Update on atypical parkinsonism
Fiona Molloy
Dublin, Ireland
Louis Tan
Singapore

15:00 – 17:00

15:00 The sensory systems control movement
John Rothwell
London, United Kingdom

15:40 Abnormalities of the sensory systems in dystonia
Ryuji Kaji
Tokushima City, Japan

16:20 Do changes in the sensory system play a role in Parkinson’s disease?
Alfredo Berardelli
Rome, Italy
At the conclusion of this session, participants should be better able to:
1. Understand the principal ways in which sensory input is used to control voluntary movement
2. Describe how demonstrated disorders of sensory processing contribute to symptoms of focal and generalized dystonia
3. Interpret how sensory deficits may contribute to motor disturbances in Parkinson’s disease
Recommended Audience: Basic scientists, Clinical academicians, Health Professionals (Non-Physician), Students/Residents/Trainees

15:00 Nosology of atypical parkinsonism
Roongroj Bhidayasiri
Bangkok, Thailand

15:40 Clinico-pathological correlation
Helen Ling
London, United Kingdom

16:20 Current treatment strategies for MSA, PSP and CBS
Maria Stamelou
Corinth, Greece
At the conclusion of this session, participants should be better able to:
1. Recognize the key clinical features of MSA, PSP and CBS
2. Review investigations that may help distinguish atypical parkinsonism
3. Discuss management strategies for atypical parkinsonism
Recommended Audience: Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees
### DBS technical and troubleshooting issues
**17:30 – 19:00**
In this interactive session, problematic DBS cases will be discussed by the audience and by the faculty consisting of a neurologist and a neurosurgeon and algorithms to improve outcome will be reviewed.
Karl Sillay  
*Madison, WI, USA*
Michael Okun  
*Gainesville, FL, USA*

At the conclusion of this session, participants should be better able to:
1. Understand stimulation induced side effects and how they can influence decision on programming
2. Define strategies in adaptation of stimulation parameters
3. Identify technical problems that need referral to the surgeon

**Recommended Audience:** Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

---

### Pediatric movement disorders
**17:30 – 19:00**
In this interactive session, participants will learn how to recognize the phenomenology of movement disorders in infants and children due to inborn errors of metabolism or infectious and autoimmune causes of encephalitis.
Mary King  
*Dublin, Ireland*
Teresa Temudo  
*Porto, Portugal*

At the conclusion of this session, participants should be better able to:
1. Recognize the phenomenology of movement disorders in infants and children
2. Identify an approach to the diagnosis of infantile onset movement disorders
3. State an approach to the diagnosis of juvenile onset movement disorders

**Recommended Audience:** Clinical academicians, Practitioners, Students/Residents/Trainees

---

### How to interpret the mysteries of RNA and mitochondrial-mediated pathophysiology in movement disorders
**17:30 – 19:00**
In this interactive session, discussion will be held on some of the emerging new ideas on the cellular pathology of movement disorders, especially in terms of mitochondrial and RNA processes and processing.
Peter Todd  
*Ann Arbor, MI, USA*
Carolyn Sue  
*Sydney, Australia*

At the conclusion of this session, participants should be better able to:
1. Describe the mechanisms and techniques used to elucidate the role of RNA in neurodegeneration
2. Understand the range of movement disorders associated with mitochondrial disease
3. Explain the techniques involved to determine mitochondrial dysfunction

**Recommended Audience:** Basic scientists, Clinical academicians, Practitioners

---

### Understanding and managing driving impairment in Parkinson’s disease
**17:30 – 19:00**
In this interactive session, typical impairments in driving performance seen in Parkinson’s disease patients will be explored and the underlying mechanisms and rational management of this important disability will be discussed.
Ergun Yasar Uc  
*Iowa City, IA, USA*
Sherrilene Classen  
*Gainesville, FL, USA*

At the conclusion of this session, participants should be better able to:
1. Discuss the common impairments in driving performance seen in Parkinson’s disease patients
2. Understand the underlying mechanisms leading to driving difficulty in Parkinson’s disease, including the contributions of impaired executive function and visual perception
3. Become familiar with the appropriate clinical evaluation and subsequent management of driving dysfunction in Parkinson’s disease

**Recommended Audience:** Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

---

### Clinical clues and pearls in the recognition of genetic forms of parkinsonism
**17:30 – 19:00**
In this interactive session, the faculty will review clinical pearls of genetic parkinsonism and present and discuss video examples of the various known forms of hereditary parkinsonism.
Daniel Healy  
*Dublin, Ireland*
Ebba Lohmann  
*Kavacik, Turkey*

At the conclusion of this session, participants should be better able to:
1. Identify red flags pointing towards genetic forms of parkinsonism
2. Distinguish between clinically typical and clinically atypical genetic forms of parkinsonism
3. Describe the pertinent clinical findings of the different forms of genetic parkinsonism and appreciate the broad phenotypic spectrum of these disorders

**Recommended Audience:** Clinical academicians, Practitioners, Students/Residents/Trainees

---

### Episodic twitches and jumps: Paroxysmal dyskinesias and the startle conditions
**17:30 – 19:00**
In this interactive session, the faculty will demonstrate different forms of paroxysmal dyskinesias and startle disorders pointing out the salient features to help recognize the different types. They will provide an update with regard to the genetic forms and secondary types and also provide guidelines to investigations using appropriate examples. Lastly, treatment strategies will be discussed again showing appropriate video examples.
Susanne Schneider  
*Lübeck, Germany*
Marina de Koning-Tijssen  
*Amsterdam, Netherlands*

At the conclusion of this session, participants should be better able to:
1. Recognize and identify different forms of paroxysmal movement disorders and startle and related conditions
2. Be updated regarding genetic advances in the primary conditions and form an approach to investigations in patients with a suspected secondary cause
3. Identify effective treatments and management strategies in different forms of paroxysmal dyskinesias and startle syndromes and related disorders

**Recommended Audience:** Basic scientists, Clinical academicians, Practitioners, Students/Residents/Trainees
WEDNESDAY, JUNE 20, 2012

5101 Plenary Session XI, cont.
At the conclusion of this session, participants should be better able to:
1. Understand the normal role of alpha-synuclein in neurons and if this role is linked to pathogenesis
2. Describe how over-expression or mutation of alpha-synuclein leads to aggregation and, potentially, spread of the pathology within the brain
3. Define how the understanding of alpha-synuclein biology informs the development of therapeutics
Recommended Audience: Basic scientists, Clinical academicians, Students/Residents/Trainees

5102 Controversies in Movement Disorders
10:00 – 11:00
Chairs: Andrew Lees, London, United Kingdom
Antonio Strafella, Toronto, ON, Canada
10:00 (YES) Animal models predict neuroprotection in Parkinson’s disease
Serge Przedborski, New York, NY, USA
10:15 (NO) Animal models predict neuroprotection in Parkinson’s disease
Anthony Lang, Toronto, ON, Canada

THURSDAY, JUNE 21, 2012

5101 Plenary Session XI
What have we learned about alpha-synuclein biology recently?
8:00 – 9:30
Chairs: Robert Edwards, San Francisco, CA, USA
Maria Grazia Spillantini, Cambridge, United Kingdom
8:00 The role of alpha-synuclein in exocytosis
Robert Edwards, San Francisco, CA, USA
8:30 Alpha-synuclein aggregation and pathogenesis in Parkinson’s disease
Maria Grazia Spillantini, Cambridge, United Kingdom
9:00 Animal models of synucleinopathy
Deniz Kirik, Lund, Sweden

5103 Blue Ribbon Highlights
11:00 – 12:00
Chairs: Christopher Goetz, Chicago, IL, USA
Timothy Lynch, Dublin, Ireland
This session will provide a critical review of the best poster presentations by a panel of experts, highlighting the relevance, novelty, and quality of both clinical and basic research presented by the delegates.
Hubert Fernandez, Cleveland, OH, USA
Jose Obeso, Pamplona, Spain

5205 Parallel Session
Gaucher’s and Parkinson’s disease: How are they linked?
15:00 – 17:00
Chairs: Dimitri Kraits, Charlestown, MA, USA
Ellen Sidransky, Bethesda, MD, USA
15:00 Glucocerebrosidase mutations as a risk factor for parkinsonism
Ellen Sidransky, Bethesda, MD, USA
15:40 How is glucocerebrosidase linked to synucleinopathies?
Dimitri Kraits, Charlestown, MA, USA
16:20 Experimental models of Gaucher’s disease: Therapeutic strategies for synucleinopathies
Gregory Grabowski, Cincinnati, OH, USA
THURSDAY, JUNE 21, 2012

5206 Parallel Session
New genes, knowledge and treatments for multiple system atrophy
15:00 – 17:00
Chairs: Glenda Halliday
Randwick, Australia
Gregor Wenning
Innsbruck, Austria

15:00 Genetic news in multiple system atrophy
Hidenao Sasaki
Naples, Italy

15:40 Progression of degeneration in multiple system atrophy
Maria Teresa Pellecchia
Buenos Aires, Argentina

16:20 Treatment developments for multiple system atrophy
Gregor Wenning
Innsbruck, Austria
At the conclusion of this session, participants should be better able to:
1. Identify new genes implicated in multiple system atrophy
2. Describe the progression of degeneration in multiple system atrophy
3. Understand new treatment developments for multiple system atrophy
Recommended Audience: Basic scientists, Clinical academicians, Practitioners

5207 Parallel Session
Markers of cognitive decline and dementia in Parkinson’s disease
15:00 – 17:00
Chairs: David John Burn
Newcastle upon Tyne, United Kingdom
Marcelo Merello
Buenos Aires, Argentina

15:00 Biochemical biomarkers of mild cognitive impairment and dementia in Parkinson’s disease
Alice Chen-Plotkin
Philadelphia, PA, USA

15:40 Neuroimaging in mild cognitive impairment and Parkinson’s disease dementia
David Brooks
London, United Kingdom

16:20 Clinical markers of dementia development in Parkinson’s disease
David John Burn
Newcastle upon Tyne, United Kingdom
At the conclusion of this session, participants should be better able to:
1. List biomarkers of cognitive impairment in non-demented Parkinson’s disease patients
2. Describe which biomarkers predict long term cognitive decline in Parkinson’s disease patients
3. Discuss which biomarkers may serve as pre-clinical biomarkers of cognitive impairment in Parkinson’s disease patients
Recommended Audience: Basic scientists, Clinical academicians, Practitioners

5208 Parallel Session
Breakthroughs in animal models in neurodegeneration
15:00 – 17:00
Chairs: Erwan Bezard
Bordeaux, France
Chenjian Li
New York, NY, USA

15:00 New animal models for Parkinson’s disease using BAC technology
Chenjian Li
New York, NY, USA

15:40 Development of transgenic monkeys using local or systemic viral vector delivery
Erwan Bezard
Bordeaux, France

16:20 The future is enhancing cell specific viral vector delivery
Deniz Dalkara
Berkeley, CA, USA
At the conclusion of this session, participants should be better able to:
1. Describe bacterial artificial chromosome (BAC) technology and its value for modeling neurodegeneration
2. Understand the capabilities of adeno-associated virus subtypes for transfecting the brain after systemic administration
3. Know the potential of “directed evolution” for producing cell-specific viral vectors with therapeutic potential
Recommended Audience: Basic scientists, Clinical academicians, Students/Residents/Trainees

5209 Parallel Session
Making sense of disability and quality of life in Parkinson’s disease
15:00 – 17:00
Chairs: Pablo Martinez-Martín
Madrid, Spain
Andrew Siderowf
Philadelphia, PA, USA

15:00 Patient-reported outcomes and Parkinson’s disease
Christopher Goetz
Chicago, IL, USA
At the conclusion of this session, participants should be better able to:
1. Understand the distinction between disability, health status, and quality of life determinants, and the science to determine the effect of the change
2. Understand how Parkinson’s disease affects patients abilities to make decisions including the decision to receive aggressive treatments and consent to research participation
Recommended Audience: Basic scientists, Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

5307 Teaching Course
Invasive therapies for advanced Parkinson’s disease
15:00 – 17:00
Chairs: Per Odin
Bremerhaven, Germany
Pierre Pollak
Geneva, Switzerland

15:00 Subcutaneous Apomorphine infusion
Erik Wolters
Amsterdam, Netherlands

15:40 Intestinal Levodopa infusion
Per Odin
Bremerhaven, Germany

16:20 Deep Brain Stimulation
Pierre Pollak
Geneva, Switzerland
At the conclusion of this session, participants should be better able to:
1. Describe methodology and expected clinical effects of the invasive therapies
2. Describe possible side effects and complications of the therapies
3. Discuss patient selection for invasive therapies, based on indications and contraindications
Recommended Audience: Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees
THRUSDAY, JUNE 21, 2012

5308 Teaching Course

The non-motor features of Parkinson’s disease
15:00 – 17:00
Chairs: Angelo Antonini
Venice, Italy
K. Ray Chaudhuri
London, United Kingdom

15:00 Phenomenology of non-motor features in Parkinson’s disease
K. Ray Chaudhuri
London, United Kingdom

15:40 How to assess the patients non-motor complaints
Angelo Antonini
Venice, Italy

16:20 Treatment of non-motor symptoms: What is available?
Tove Henriksen
Copenhagen, Denmark

At the conclusion of this session, participants should be better able to:
1. Describe the different types of non-motor features of Parkinson’s disease
2. Evaluate the importance of non-motor features and assess their severity with validated tools
3. Recognize the need of therapy for non-motor features and select appropriate medications

Recommend Audience: Basic scientists, Clinical academicians, Practitioners, Health Professionals (Non-Physician), Students/Residents/Trainees

GUIDED POSTER TOURS:

Guided Poster Tours will give small groups of delegates an opportunity to hear discussion on a select group of abstracts in several sub-categories.

Delegates interested in attending a Guided Poster Tour may sign up and receive a tour ticket at the MDS Desk beginning Sunday, June 17. Attendance is limited, and tickets will be given on a first-come, first-served basis. Delegates are encouraged to sign up early to ensure availability.

There will be four simultaneous tours per day from Monday, June 18 through Thursday, June 21.

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, June 18</td>
<td>12:45 – 14:15</td>
</tr>
<tr>
<td>Tuesday, June 19</td>
<td>12:15 – 13:45</td>
</tr>
<tr>
<td>Wednesday, June 20</td>
<td>12:00 – 13:30</td>
</tr>
<tr>
<td>Thursday, June 21</td>
<td>12:00 – 13:30</td>
</tr>
</tbody>
</table>

A complete schedule with specific topic dates and times will be available soon, at www.mdscongress2012.org/
FACULTY LISTING

Aarsland, Dag
Stavanger, Norway
4210

Adler, Charles
Scottsdale, AZ, USA
5102

Altenmüller, Eckart
Hannover, Germany
4211

Anderson, Karen
Baltimore, MD, USA
2308

Antonini, Angelo
Venice, Italy
5308

Ascherio, Alberto
Boston, MA, USA
2207

Barker, Roger
Cambridge, United Kingdom
2209, 4210

Beal, M. Flint
New York, NY, USA
3103

Berardelli, Alfredo
Rome, Italy
4212

Berg, Daniela
Tübingen, Germany
4104

Bezard, Erwan
Bordeaux, France
5208

Bhatia, Kailash
London, United Kingdom
3510

Bhatt, Mohit
Mumbai, India
4307

Bhidayasiri, Roongroj
Bangkok, Thailand
4308

Bloem, Bastiaan
Nijmegen, Netherlands
2103

Bohnen, Nicolaas
Saline, MI, USA
2208

Bonifati, Vincenzo
Rotterdam, Netherlands
3404

Boxer, Adam
San Francisco, CA, USA
3210

Bressman, Susan
New York, NY, USA
3508

Brodky, Matthew
Portland, OR, USA
4509

Brooks, David
London, United Kingdom
5207

Burn, David
Newcastle upon Tyne, United Kingdom
5207

Cahill, Dolores
Dublin, Ireland
3210

Cardoso, Francisco
Belo Horizonte, Brazil
4211

Chaudhuri, K. Ray
London, United Kingdom
5308

Chen-Plotkin, Alice
Philadelphia, PA, USA
5207

Cicchetti, Francesca
Quebec, PQ, Canada
2207

Classen, Sherrilene
Gainesville, FL, USA
4406

Counihan, Timothy
Galway, Ireland
1108

Dale, Russell
Sydney, Australia
2210

Dalkara, Deniz
Berkeley, CA, USA
5208

Davey, Gavin
Dublin, Ireland
3207

De Koning-Tijssen, Marina
Amsterdam, Netherlands
4508

Deuschl, Günther
Kiel, Germany
3104, 4103, 4208

Edwards, Mark
London, United Kingdom
2308

Edwards, Robert
San Francisco, CA, USA
5101

Elble, Rodger
Springfield, IL, USA
4208

Espay, Alberto
Cincinnati, OH, USA
3510

Fabbrini, Giovanni
Rome, Italy
3310

Fahn, Stanley
New York, NY, USA
2209

Farrell, Michael
Dublin, Ireland
3403

Farrer, Matthew
Vancouver, BC, Canada
2103

Fernandez, Hubert
Cleveland, OH, USA
5103

Ferreira, Joaquim
Lisbon, Portugal
3104

Follett, Ken
Omaha, NE, USA
1106

Foltynie, Thomas
London, United Kingdom
2209

Fox, Susan
Toronto, ON, Canada
3310

Fraix, Valerie
Saint Martin D’Heres, France
3209

Friedman, Joseph
Barrington, RI, USA
2509

Frucht, Steven
New York, NY, USA
4509

Fung, Victor
Westmead, Australia
3403, 4209

Gasser, Thomas
Tübingen, Germany
2206

Gershanik, Oscar
Buenos Aires, Argentina
4307

Giladi, Nir
Tel Aviv, Israel
3407

Goetz, Christopher
Chicago, IL, USA
5103, 5209

Goldman, Jennifer
Chicago, IL, USA
4210

Grabowski, Gregory
Cincinnati, OH, USA
5205

Greenamyre, J. Timothy
Pittsburgh, PA, USA
3207

Grosset, Donald
Glasgow, United Kingdom
1105

Hallett, Mark
Bethesda, MD, USA
2308
FACULTY LISTING

<table>
<thead>
<tr>
<th>Name</th>
<th>Nationality</th>
<th>City, Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>Halliday, Glenda</td>
<td>Australia</td>
<td>Randwick, Australia</td>
</tr>
<tr>
<td>Hardy, John</td>
<td>United Kingdom</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Harrington, Hugh</td>
<td>Ireland</td>
<td>Cork, Ireland</td>
</tr>
<tr>
<td>Healy, Daniel</td>
<td>Ireland</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>Henriksen, Tove</td>
<td>Denmark</td>
<td>Copenhagen, Denmark</td>
</tr>
<tr>
<td>Ho, Shu-Leong</td>
<td>Hong Kong</td>
<td>Hong Kong</td>
</tr>
<tr>
<td>Horak, Fay</td>
<td>Ireland</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>Hutchinson, Michael</td>
<td>Ireland</td>
<td>Cork, Ireland</td>
</tr>
<tr>
<td>Jankovic, Joseph</td>
<td>United States</td>
<td>Houston, TX, USA</td>
</tr>
<tr>
<td>Kaji, Ryuji</td>
<td>Japan</td>
<td>Tokushima City, Japan</td>
</tr>
<tr>
<td>Katzenschlager, Regina</td>
<td>Austria</td>
<td>Vienna, Austria</td>
</tr>
<tr>
<td>Kimber, Thomas</td>
<td>Australia</td>
<td>Adelaide, Australia</td>
</tr>
<tr>
<td>King, Mary</td>
<td>Ireland</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>Kirik, Deniz</td>
<td>Sweden</td>
<td>Lund, Sweden</td>
</tr>
<tr>
<td>Klein, Christine</td>
<td>Germany</td>
<td>Lübeck, Germany</td>
</tr>
<tr>
<td>Krack, Paul</td>
<td>France</td>
<td>Grenoble, France</td>
</tr>
<tr>
<td>Krainc, Dimitri</td>
<td>USA</td>
<td>Charlestown, MA, USA</td>
</tr>
<tr>
<td>Kulisevsky, Jaime</td>
<td>Spain</td>
<td>Barcelona, Spain</td>
</tr>
<tr>
<td>Lang, Anthony</td>
<td>Canada</td>
<td>Toronto, ON, Canada</td>
</tr>
<tr>
<td>Lee, Mark</td>
<td>United Kingdom</td>
<td>Sunderland, United Kingdom</td>
</tr>
<tr>
<td>Lee, Virginia</td>
<td>USA</td>
<td>Philadelphia, PA, USA</td>
</tr>
<tr>
<td>Lees, Andrew</td>
<td>United Kingdom</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Lehericy, Stephane</td>
<td>France</td>
<td>Paris, France</td>
</tr>
<tr>
<td>Leigh, R. John</td>
<td>USA</td>
<td>Cleveland, OH, USA</td>
</tr>
<tr>
<td>Leonardi, Matilde</td>
<td>Italy</td>
<td>Milano, Italy</td>
</tr>
<tr>
<td>Li, Chenjian</td>
<td>USA</td>
<td>New York, NY, USA</td>
</tr>
<tr>
<td>Lim, Erle Chuen-Hian</td>
<td>Singapore</td>
<td>Singapore</td>
</tr>
<tr>
<td>Lim, Shen-Yang</td>
<td>Malaysia</td>
<td>Kuala Lumpur, Malaysia</td>
</tr>
<tr>
<td>Ling, Helen</td>
<td>United Kingdom</td>
<td>London, United Kingdom</td>
</tr>
<tr>
<td>Litvan, Irene</td>
<td>USA</td>
<td>La Jolla, CA, USA</td>
</tr>
<tr>
<td>Lohmann, Ebba</td>
<td>Turkey</td>
<td>Istanbul, Turkey</td>
</tr>
<tr>
<td>Lohmann, Katja</td>
<td>Germany</td>
<td>Lübeck, Germany</td>
</tr>
<tr>
<td>Louis, Elan</td>
<td>USA</td>
<td>New York, NY, USA</td>
</tr>
<tr>
<td>Lynch, Timothy</td>
<td>Ireland</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>Mackenzie, Ian</td>
<td>Canada</td>
<td>Vancouver, BC, Canada</td>
</tr>
<tr>
<td>Magennis, Brian</td>
<td>Ireland</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>Marks, William</td>
<td>USA</td>
<td>San Francisco, CA, USA</td>
</tr>
<tr>
<td>Marsh, Laura</td>
<td>USA</td>
<td>Houston, TX, USA</td>
</tr>
<tr>
<td>Martinez-Martino, Pablo</td>
<td>Spain</td>
<td>Madrid, Spain</td>
</tr>
<tr>
<td>Martino, Davide</td>
<td>Italy</td>
<td>Bari, Italy</td>
</tr>
<tr>
<td>Meinck, Hans-Michael</td>
<td>Germany</td>
<td>Heidelberg, Germany</td>
</tr>
<tr>
<td>Merello, Marcelo</td>
<td>Argentina</td>
<td>Buenos Aires, Argentina</td>
</tr>
<tr>
<td>Micheli, Federico</td>
<td>Argentina</td>
<td>Buenos Aires, Argentina</td>
</tr>
<tr>
<td>Misra, Usha</td>
<td>India</td>
<td>Lucknow, India</td>
</tr>
<tr>
<td>Miyasaki, Janis</td>
<td>Canada</td>
<td>Toronto, ON, Canada</td>
</tr>
<tr>
<td>Molloy, Fiona</td>
<td>Ireland</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>Moore, A. Peter</td>
<td>United Kingdom</td>
<td>Liverpool, United Kingdom</td>
</tr>
<tr>
<td>Mulcahy, Riona</td>
<td>Ireland</td>
<td>Waterford, Ireland</td>
</tr>
<tr>
<td>Munneke, Marten</td>
<td>Netherlands</td>
<td>Nijmegen, Netherlands</td>
</tr>
<tr>
<td>Murphy, Raymond</td>
<td>Ireland</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>Obeso, Jose</td>
<td>Spain</td>
<td>Pamplona, Spain</td>
</tr>
<tr>
<td>Okun, Michael</td>
<td>USA</td>
<td>Gainesville, FL, USA</td>
</tr>
<tr>
<td>Olanow, C. Warren</td>
<td>USA</td>
<td>New York, NY, USA</td>
</tr>
<tr>
<td>Onofrj, Marco</td>
<td>Italy</td>
<td>Pescara, Italy</td>
</tr>
<tr>
<td>Petronis, Art</td>
<td>Ireland</td>
<td>Dublin, Ireland</td>
</tr>
<tr>
<td>Pellecchia, Maria Teresa</td>
<td>Italy</td>
<td>Naples, Italy</td>
</tr>
<tr>
<td>Poewe, Werner</td>
<td>Austria</td>
<td>Innsbruck, Austria</td>
</tr>
<tr>
<td>Name</td>
<td>City/Country</td>
<td>Zip Code</td>
</tr>
<tr>
<td>-----------------------</td>
<td>-----------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>Pollak, Pierre</td>
<td>Geneva, Switzerland</td>
<td>5307</td>
</tr>
<tr>
<td>Przedborski, Serge</td>
<td>New York, NY, USA</td>
<td>5102</td>
</tr>
<tr>
<td>Quinn, Niall</td>
<td>London, United Kingdom</td>
<td>3403</td>
</tr>
<tr>
<td>Rajput, Alexander</td>
<td>Saskatoon, SK, Canada</td>
<td>4208</td>
</tr>
<tr>
<td>Rascol, Olivier</td>
<td>Toulouse, France</td>
<td>1105, 4104</td>
</tr>
<tr>
<td>Ravina, Bernard</td>
<td>Cambridge, MA, USA</td>
<td>2104</td>
</tr>
<tr>
<td>Robinson, Phil</td>
<td>Leeds, United Kingdom</td>
<td>2206</td>
</tr>
<tr>
<td>Rochester, Lynn</td>
<td>Newcastle upon Tyne, United Kingdom</td>
<td>2208</td>
</tr>
<tr>
<td>Rothwell, John</td>
<td>London, United Kingdom</td>
<td>4212</td>
</tr>
<tr>
<td>Rucker, Janet</td>
<td>New York, NY, USA</td>
<td>3509</td>
</tr>
<tr>
<td>Sasaki, Hidenao</td>
<td>Hokkaido, Japan</td>
<td>5206</td>
</tr>
<tr>
<td>Saunders-Pullman, Rachel</td>
<td>New York, NY, USA</td>
<td>2403</td>
</tr>
<tr>
<td>Scherfler, Christoph</td>
<td>Innsbruck, Austria</td>
<td>2309</td>
</tr>
<tr>
<td>Schneider, Susanne</td>
<td>Lübeck, Germany</td>
<td>4508</td>
</tr>
<tr>
<td>Schnitzler, Alfons</td>
<td>Düsseldorf, Germany</td>
<td>4208</td>
</tr>
<tr>
<td>Schwarzschild, Michael</td>
<td>Sharon, MA, USA</td>
<td>1105</td>
</tr>
<tr>
<td>Seppi, Klaus</td>
<td>Innsbruck, Austria</td>
<td>1108</td>
</tr>
<tr>
<td>Shamir, Ron</td>
<td>Tel Aviv, Israel</td>
<td>2206</td>
</tr>
<tr>
<td>Siderowf, Andrew</td>
<td>Philadelphia, PA, USA</td>
<td>5209</td>
</tr>
<tr>
<td>Sidransky, Ellen</td>
<td>Bethesda, MD, USA</td>
<td>5205</td>
</tr>
<tr>
<td>Sillay, Karl</td>
<td>Madison, WI, USA</td>
<td>4403</td>
</tr>
<tr>
<td>Smith, Steve</td>
<td>Norfolk, United Kingdom</td>
<td>2405</td>
</tr>
<tr>
<td>Grazia Spillantini, Maria</td>
<td>Cambridge, United Kingdom</td>
<td>5101</td>
</tr>
<tr>
<td>Stamelou, Maria</td>
<td>Corinth, Greece</td>
<td>4308</td>
</tr>
<tr>
<td>Starr, Philip</td>
<td>San Francisco, CA, USA</td>
<td>1106</td>
</tr>
<tr>
<td>Stern, Gerald</td>
<td>London, United Kingdom</td>
<td>4211</td>
</tr>
<tr>
<td>Stern, Matthew</td>
<td>Philadelphia, PA, USA</td>
<td>2103, 4103, 4104</td>
</tr>
<tr>
<td>Stoessl, A. Jon</td>
<td>Vancouver, BC, Canada</td>
<td>3208</td>
</tr>
<tr>
<td>Stone, Jon</td>
<td>Edinburgh, United Kingdom</td>
<td>2308</td>
</tr>
<tr>
<td>Strafella, Antonio</td>
<td>Toronto, ON, Canada</td>
<td>3208, 5102</td>
</tr>
<tr>
<td>Studer, Lorenz</td>
<td>New York, NY, USA</td>
<td>2209</td>
</tr>
<tr>
<td>Sue, Carolyn</td>
<td>Sydney, Australia</td>
<td>4404</td>
</tr>
<tr>
<td>Sulzer, David</td>
<td>New York, NY, USA</td>
<td>3207</td>
</tr>
<tr>
<td>Surmeier, D. James</td>
<td>Chicago, IL, USA</td>
<td>3207</td>
</tr>
<tr>
<td>Tabrizi, Sarah</td>
<td>London, United Kingdom</td>
<td>4307</td>
</tr>
<tr>
<td>Tan, Louis</td>
<td>Singapore</td>
<td>4308</td>
</tr>
<tr>
<td>Tarsy, Daniel</td>
<td>Boston, MA, USA</td>
<td>2509</td>
</tr>
<tr>
<td>Teive, Helio</td>
<td>Curitiba, Brazil</td>
<td>2408</td>
</tr>
<tr>
<td>Temudo, Teresa</td>
<td>Porto, Portugal</td>
<td>4405</td>
</tr>
<tr>
<td>Thompson, Philip</td>
<td>Adelaide, Australia</td>
<td>2404</td>
</tr>
<tr>
<td>Timmermann, Lars</td>
<td>Kœln, Germany</td>
<td>1106</td>
</tr>
<tr>
<td>Todd, Peter</td>
<td>Ann Arbor, MI, USA</td>
<td>4404</td>
</tr>
<tr>
<td>Tolosa, Eduardo</td>
<td>Barcelona, Spain</td>
<td>2404</td>
</tr>
<tr>
<td>Toni, Ivan</td>
<td>Nijmegen, Netherlands</td>
<td>2208</td>
</tr>
<tr>
<td>Trojanowski, John</td>
<td>Philadelphia, PA, USA</td>
<td>2104</td>
</tr>
<tr>
<td>Uc, Ergun</td>
<td>Iowa City, IA, USA</td>
<td>4406</td>
</tr>
<tr>
<td>Uitti, Ryan</td>
<td>Jacksonville, FL, USA</td>
<td>2407</td>
</tr>
<tr>
<td>Van De Warrenburg, Bart</td>
<td>Nijmegen, Netherlands</td>
<td>3103</td>
</tr>
<tr>
<td>Van Hilten, Bob</td>
<td>Leiden, Netherlands</td>
<td>2407</td>
</tr>
<tr>
<td>Vincent, Angela</td>
<td>Headington, United Kingdom</td>
<td>4209</td>
</tr>
<tr>
<td>Visser-Vandewalle, Veerle</td>
<td>Maastricht, Netherlands</td>
<td>3209</td>
</tr>
<tr>
<td>Volkmann, Jens</td>
<td>Würzburg, Germany</td>
<td>3209</td>
</tr>
<tr>
<td>Weintraub, Daniel</td>
<td>Ardmore, PA, USA</td>
<td>1107</td>
</tr>
<tr>
<td>Wenning, Gregor</td>
<td>Innsbruck, Austria</td>
<td>5206</td>
</tr>
<tr>
<td>Wolters, Erik</td>
<td>Amsterdam, Netherlands</td>
<td>5307</td>
</tr>
<tr>
<td>Wszolek, Zbigniew</td>
<td>Jacksonville, FL, USA</td>
<td>3309</td>
</tr>
</tbody>
</table>
EDUCATION INFORMATION

To better fulfill its global mission of advancing the neurological sciences as they relate to the field of Movement Disorders, MDS is continually expanding its educational program. This growing program offers an increasing variety of high caliber continuing medical education and continuing professional development opportunities in movement disorders.

Visiting Professor Program
This program is intended to provide an excellent educational opportunity in movement disorders to regions of the world not adequately served by resources within that region. Applications will be considered by the MDS Education Committee. For more details, visit www.movementdisorders.org/education/ or e-mail education@movementdisorders.org.

Ambassador Program
This program is intended to provide excellent faculty in the field of Movement Disorders to existing conferences around the world. Applications will be considered by the MDS Education Committee. For more details, visit www.movementdisorders.org/education/ or e-mail education@movementdisorders.org.

Regional Outreach
More educational support opportunities are available through the MDS regional sections: the Asian and Oceanian Section (AOS), the European Section (ES), and the Pan American Section (PAS). For more information, please e-mail education@movementdisorders.org.

Online CME Activities

Journal CME
Visit the Educational Resources page on the MDS website to view a list of Movement Disorders Journal articles available for CME credit. MDS is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide certified continuing medical education for physicians. MDS designates these educational activities for a maximum of 1.0 AMA PRA Category 1 Credit™ each. Physicians should only claim credit commensurate with the extent of their participation in the activity. For further information, visit www.movementdisorders.org/education/.

Coffee Break CME
New in 2012 is The Movement Disorder Society’s first online CME program specially designed for the busy clinician—Coffee Break CME. For physicians who care for Parkinson’s disease (PD) and movement disorders patients, continuing education is critical to providing the best care possible. This program is designed to provide this information in a modular format where each module is focused on a single topic that can be completed in a short period of time and provide the clinician with updated information that is relevant to their practice. Both standard approaches and new advances will be highlighted.

Each module is broken into sub-topics that are discussed in a short article and demonstrated in 1-5 case study videos. The scope of this project includes modules on: parkinsonism, tremor, dystonia, chorea, restless legs syndrome, and other topics as identified. These modules will be rolled out over several months, beginning with three modules covering tremor. After users have registered for a module, they are able to log in to the site as many times as needed to view all the material. At the beginning and completion of each module, participants are asked content-related questions to gauge their learning. MDS is accredited by the ACCME to certify 2.0 AMA PRA Category 1 Credits™ for each module.

Webcasts
In alignment with its educational mission, MDS provides a number of educational webcasts. These webcasts help expand the outreach of our educational offerings. The following webcasts are now available:

Edward I. Rudman Parkinson’s Disease Patient and Caregiver Symposium: Non Motor Aspects of Parkinson’s Disease
This webcast was created from the Edward I. Rudman Parkinson’s Disease Patient and Caregiver Symposium: Non Motor Aspects of Parkinson’s Disease, which took place on October 31, 2009 at The Conference Center at Harvard Medical Center in Boston. Topics covered include important non-motor aspects of Parkinson’s disease such as depression, anxiety, sleep disorders, autonomic disturbances, and cognitive deficits which often impact the quality of life of patients with Parkinson’s disease as much as or even more than motor symptoms. Intended for patients and caregivers.

De Novo Parkinson’s Disease: Diagnosis and Treatment Webcast
MDS sponsored a course entitled De Novo Parkinson’s Disease: Diagnosis and Treatment at the University of Lisbon Faculty of Medicine in Lisbon, Portugal, April 26, 2010, and was attended by over 100 neurologists. The resulting webcast covers a wide variety of topics, including the natural history of PD, diagnosing PD, disease modifying strategies in PD, and management of non-motor problems in early PD. This course is available for Society Members only. Intended for general neurologists, geriatricians and general practitioners.

KUMC 4th Annual Parkinson’s Disease Symposium Webcast
The University of Kansas Medical Center’s Parkinson’s Disease and Movement Disorder Center hosted the 4th Annual Parkinson’s Disease Symposium on August 21, 2010 in Kansas City, Kansas, and was attended by over 800 people. The webcast created from this event features basic information on the diagnosis, symptoms and treatment of Parkinson’s disease,
novel interventions, potential benefits of deep brain stimulation, sleep problems in PD, benefits of exercise, and understanding the concept of slowing progression of PD. Intended for patients and caregivers.

14th International Congress on Parkinson’s Disease and Movement Disorders - Update on Dystonia Webcast

This webcast, captured during the 14th International Congress, June 14, 2010, covers the spectrum of dystonias, providing insight into their diagnosis and treatment. The course begins with the classification into primary and secondary dystonias, followed by further examination into genetic, heredodegenerative and paroxysmal dystonias. This program has a special emphasis on the various phenotypes of genetic forms of dystonia, including the recently discovered forms associated with DYT6. Secondary dystonia is described with detailed clinical syndromic associations.

Other Online Education Activities

MDS provides a variety of online educational activities in addition to webcasts and CME programming. The following educational tools are available on the MDS website.

Slide Sets

This Members-only service familiarizes learners with the differential diagnosis and clinical features that define various common involuntary movements, as well as the course of treatment and complications of movement disorders. Slide sets are available at [www.movementdisorders.org/education/](http://www.movementdisorders.org/education/).

Current Slide Sets
- Ataxia (PPT)
  - Jennifer G. Goldman, MD
- Chorea (PPT)
  - Kathleen M. Shannon, MD
- The Diagnosis and Management of Dystonia (PPT)
  - Steven J. Frucht, MD
- Myoclonus: Diagnosis and Treatment (PPT)
  - Steven J. Frucht, MD
- Parkinsonism (PPT)
  - Kathleen M. Shannon, MD * Now available in Spanish.
- Restless Legs Syndrome (PPT)
  - Charles H. Adler, MD, PhD
- Tics and Tourette Syndrome (PPT)
  - Jennifer G. Goldman, MD

MDS Video Library

This Members-only library consists of video supplements from the Movement Disorders journal since 1986. You may search the Video Library by keyword, author, volume and issue, or a combination of these fields. The Video Library is available at [www.movementdisorders.org/education/](http://www.movementdisorders.org/education/).

Case of the Month

Case of the Month (COM) is the MDS interactive online feature that presents unique and challenging movement disorders cases. MDS members are invited to answer questions after analyzing the video and case history, and are provided with the expert analysis. Please visit the MDS website to view this month’s case.

MDS is currently accepting submissions for Case of the Month. Case of the Month provides an opportunity for members to share interesting cases for educational purposes in a forum dedicated to movement disorders experts. For information about submission requirements, including video format and patient consent forms, please visit the MDS website at [www.movementdisorders.org/education/](http://www.movementdisorders.org/education/).

Live Courses

Update on the Pathogenesis and Treatment of Parkinson’s Disease and Related Disorders

March 4, 2012 – La Paz, Bolivia
Course Director: Janeth Laguna

Registration available online.

The purpose of this course is to offer a forum for clinical and surgical discussion on Parkinson’s disease and on a variety of movement disorder topics, including the presentation of current research and available treatments. A group of sessions with specific themes has been selected, allowing participants to have an educational and comprehensive overview on subjects of broad interest to the community, in turn helping us to improve the quality of life of our patients.

Target audience: Movement disorder specialists, general neurologists, general physicians, physicians in training, and students

Dopamine Transporter Imaging in Neurological Practice

March 31, 2012 – Santa Clara, CA, USA
Course Director: Caroline Tanner

Registration available online.

This workshop is part of a series of four courses designed to introduce participants to the potential of dopamine transporter single photon emission computed tomography imaging in neurological practice and help to answer some of the questions posed by clinicians, researchers, managers, and patients about the appropriate use of dopamine transporter imaging. It aims to present a balanced view of dopamine transporter imaging studies, still in their infancy and perhaps subject to intrinsic variability different from, but not necessarily better than, available clinical measures. The scope of information to be presented and discussed has been chosen to not only identify the potential usefulness of dopamine transporter imaging in neurological practice, but also to guard against indiscriminate
and injudicious use of dopamine transporter imaging, or erroneous interpretation of findings.

Target audience: Movement disorder specialists, general neurologists, and nuclear medicine specialists

**Bloomsday Basic Movement Disorders Course**
June 16, 2012 – Dublin, Ireland
Course Directors: Sean O’Riordan, Timothy Lynch
Please see page 35

**5th Annual MDS-ES Summer School for Young Neurologists**
July 6-8, 2012 – Paris, France
Course Directors: Marie Vidalhiet, Bastiaan Bloem, Joaquim Ferreira
Applications are due April 16, 2012.
Visit [www.movementdisorders.org/education](http://www.movementdisorders.org/education) for more information.

This program is an extensive, interactive course for young neurologists from Europe and Africa, offering a unique opportunity for hands-on examination of a wide variety of patients with movement disorders, overseen by a faculty of international experts in the field of Movement Disorders.

Target audience: Young neurologists within five years of their completion of general neurological training who are interested in specializing in Movement Disorder and young neurologists who are already training in Movement Disorders.

**Botulinum Toxin Training Course**
August 24-25, 2012 – Manila, Philippines
Course Director: Raymond Rosales

Registration available online.

Despite increasingly widespread use of botulinum toxins (BtX for neurological, rehabilitation, and other disorders), there is rarely a recognized or regularly available training scheme on this topic in the Asian and Oceanian region. This two day workshop is intended to address this practice gap through didactic lecture from international experts, interactive case discussions, and a patient practicum.

Target audience: Medical practitioners in the relevant fields with a working knowledge of diagnosis and general management of the various conditions

For more information about any of these courses, please visit [www.movementdisorders.org/education/](http://www.movementdisorders.org/education/) or e-mail education@movementdisorders.org.

---

Please share the following information with your patients regarding upcoming patient group meetings in conjunction with the 16th International Congress:

**The Parkinson’s Association of Ireland hosts**

**Parkinson’s Patient Information Day**
Sunday, June 17, 2012 • 11:00 – 16:00
Convention Centre Dublin

The Parkinson’s Association of Ireland is honored to host a very special Parkinson’s Patient Information Day on June 17, 2012 to coincide with the 16th MDS International Congress. This is an exciting opportunity for people with PD to listen to world renowned speakers on PD.

**Topics and speakers will include:**

- Parkinson’s Disease from James Parkinson to Current Day
  - Prof. Stanley Fahn, MD
- The Drug Management of Parkinson’s
  - Prof. Werner Poewe, MD
- Growing Old with Parkinson’s – Principles and Considerations
  - Dr. Graham Hughes, MB, MRCPI
- Depression and Compulsive Behaviour in Parkinson’s
  - Prof. David John Burn, MD, FRCP
- Deep Brain Stimulation in Parkinson’s
  - Prof. Philip Starr, MD, PhD
- Future Directions of Parkinson’s
  - Prof. Olivier Rascol, MD, PhD
- Practical Advice for Day to Day Living with Parkinson’s
  - Mr. Brian Magennis, RN

**www.parkinsons.ie**

To register for the meeting please contact Una Anderson Ryan at 353(0)87 251 1156.

**Dystonia Ireland Conference**

**The Round Room Mansion House Dublin**
Sunday 17th June 2012

We are delighted to inform you that our Conference will take place on Sunday, 17th June 2012 in The Round Room, Mansion House Dublin with registration taking place from 9.15 a.m. concluding at 4.30 p.m. The Conference itself will commence at 10.00 a.m. with international speakers from Europe and the United States of America.

For further information and registration details please contact Maria Hickey, Dystonia Ireland, 33, Larkfield Grove, Harold’s Cross, Dublin 6W Ireland. Tel: 003531 4922514 E-mail: info@dystonia.ie www.dystonia.ie
INTERNATIONAL CONGRESS DVDS

Available for Pre-Order

MDS is pleased to offer you the opportunity to pre-order the DVDs of the Congress Teaching Courses, the Congress Themed Sessions and the MDS Video Games with your Congress registration. Each DVD includes slides, audio and video and the accompanying syllabi.

Congress Teaching Course DVD
There are eight Teaching Courses:
- Invasive therapies for advanced Parkinson’s disease
- The non-motor features of Parkinson’s disease
- The genetics of frontotemporal dementias/tauopathies*
- Update on atypical parkinsonism
- Update on chorea
- Update on diagnosis and management of early parkinsonism
- Update on levodopa-induced dyskinesias
- Update on psychogenic movement disorders

*Also a Themed Session

<table>
<thead>
<tr>
<th>Teaching Course DVD</th>
<th>Pre-Order Price (USD)</th>
<th>Full Price (USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDS Members</td>
<td>$ 50.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Non-Members</td>
<td>$100.00</td>
<td>$200.00</td>
</tr>
</tbody>
</table>

Congress Themed Session DVD
The Special Meeting Theme of the 2012 MDS Congress is The Perils and Promises of Genetics in Movement Disorders. There are 13 Themed Sessions which include:

Parallel Sessions
- Imaging genetics in movement disorders
- Is Parkinson’s disease a mitochondrial or proteostatic disorder?
- Molecular methodology for dummies: New investigative tools to shake up our understanding of Parkinson’s disease
- What is essential tremor?
- Whatever happened to environmental factors in the etiology of Parkinson’s disease? Are they still important?

Plenary Sessions
- Is it time to change how we define Parkinson’s disease?
- Lost in translation: Has genetics informed our knowledge of non-parkinsonian movement disorders?

Skills Workshop
- How to critically read and interpret genetic and molecular biological literature in movement disorders (e.g. GWAS studies)
- How to interpret the mysteries of RNA and mitochondrial-mediated pathophysiology in movement disorders
- Is my movement disorder genetic and what does that mean for me and my family?

Teaching Course
- The genetics of frontotemporal dementias/tauopathies

Video Sessions
- Clinical clues and pearls in the recognition of genetic forms of parkinsonism
- Clinical clues and pearls in the recognition of the primary dystonias and dystonia plus syndromes: Genotype-Phenotype correlation

<table>
<thead>
<tr>
<th>Congress Themed Session DVD</th>
<th>Pre-Order Price (USD)</th>
<th>Full Price (USD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MDS Members</td>
<td>$ 62.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Non-Members</td>
<td>$125.00</td>
<td>$250.00</td>
</tr>
</tbody>
</table>

MDS Video Games DVD
MDS is pleased to offer you the opportunity to pre-order a DVD-ROM of the MDS Video Games held on Wednesday, June 20, 2012 at the 16th International Congress. Each DVD includes all 3 of the presentations.

$25 USD plus $5 USD shipping and handling

Pre-orders are available through the Registration process. Distribution of DVDs will begin in November 2012. DVDs will be shipped to the address you provide during the Congress registration process.

Also available for purchase:
- 2011 Congress Teaching Course DVD
- 2011 Congress Themed Session DVD
- 2011 VO Games DVD
- 2010 Congress Teaching Course DVD

For rates and ordering information please visit: www.movementdisorders.org/education/multimedia.php.
MEMBERSHIP INFORMATION

Membership Benefits
• A subscription to the print, DVD, and online journal, *Movement Disorders*, including supplemental publications, such as The Movement Disorder Society Evidence Based Medicine Review: Treatments for Motor and Non-Motor Symptoms of Parkinson’s Disease.
• A unique selection of educational opportunities, including live and online CME/CPD activities and reference material on topics in Movement Disorders.
• Reduced fees for participation in the Society’s educational programs. Educational Programs include the annual International Congress of Parkinson’s Disease and Movement Disorders, and regional programs, courses and workshops held each year.
• A searchable online and mobile directory listing mailing addresses, telephone and fax numbers, and e-mail addresses for members.
• A Members Only Section of the MDS website including a searchable Video Library, Case of the Month, teaching slide sets, and one-time login access to full text articles in the *Movement Disorders* Journal.
• A quarterly newsletter entitled, *Moving Along*, highlighting current news and views in the field of Movement Disorders.
• Participation in the election of international and regional section leadership representatives.

FREE Membership! Non-Members Applying for Membership
Non-Members will have the opportunity to apply for MDS membership at the International Congress for no additional fee with limited benefits through 2012, and full membership status, receiving the print journal, in January of 2013. Membership applications will be provided to all non-member attendees onsite with their registration packet and must be returned to the MDS desk prior to the conclusion of the International Congress. No applications will be accepted by the Secretariat after June 21, 2012. *Participants paying the Non-Member registration fee will be eligible to apply for membership at no additional cost. This option is not available to those registering as a Junior Participant or a Health Professional (Non-Physician) or anyone who registered as part of a group. Only those who have not previously been members of MDS will be eligible to apply.*

2012-2013 will be another exciting year for MDS and we look forward to bringing you news of these and other new initiatives through the *Movement Disorders* journal, *Moving Along* newsletter and the MDS website.

For further information, please contact:
The Movement Disorder Society
International Secretariat
555 East Wells Street, Suite 1100
Milwaukee, WI 53202 USA
Tel: + 1 414-276-2145
Fax: + 1 414-276-3349
E-mail: info@movementdisorders.org
Website: www.movementdisorders.org
TOP ATTRACTIONS IN DUBLIN

Trinity College
Founded by Queen Elizabeth I in 1592, Trinity College is Ireland’s most famous college, and is located within walking distance of the Convention Centre. Here, you can take a guided walking tour of the beautiful campus, led by one of the students (please check for times / availability). Trinity College’s biggest attractions include the Book of Kells in the Old Library and a 15th century harp, the oldest harp in Ireland.

National Museum
Just south of Trinity College, the National Museum houses some of the largest collections of Irish artifacts. Recording Ireland’s history from the Stone Age to today, visitors will find Celtic jewelry, Irish art, Viking artifacts, and detailed exhibitions. The building itself is a piece of art on its own, with a large rotunda, marble pillars, and mosaic floors.

Dublin Castle
Originally a Viking fortress, the Dublin Castle now serves as an administrative and historical site. The State Apartments are open for visitors who wish to learn more about British rule in Ireland. Many smaller museums are contained within Dublin Castle, including The Revenue Museum, The Garda (Police) Museum, the Chapel Royal, and the Cheater Beatty Library.

Grafton Street
This popular and fashionable shopping area has a variety of department stores, restaurants, and cafes to explore, including the famous Bewley’s Oriental Café. The street is blocked off from traffic for a pedestrian and tourist friendly shopping experience. Walking south on Grafton Street will take you to St. Stephen’s Green, a beautiful 22 acre enclosed park that offers a quiet refuge for tourists and Dubliners alike.

Phoenix Park
An urban park in Dublin, lying 2–4 km west of the city centre, just north of the River Liffey, is one of the largest walled city parks in Europe. The park includes large areas of grassland and tree-lined avenues, and is home to a herd of wild Fallow deer.

Number Twenty Nine Georgian House Museum
Located within walking distance of the Convention Centre, this home was first built in 1794 and was opened as a museum in 1991. Refurnished with original furniture and décor from the time period, visitors will experience firsthand the elegance of the wealthy Dublin elite in the late 18th century.

Merrion Square
This 12 acre Georgian square is within walking distance of the Convention Centre and offers a beautiful view of the famous 18th century terrace homes and their brightly colored doors. Merrion Square is also home to the National Gallery, a free museum containing over 15,000 Irish and European artworks, as well as the Natural History Museum.

St. Patricks Cathedral and Marsh’s Library
Origin of Jonathan Swift’s Gulliver’s Travels, Marsh’s Library is situated in St. Patrick’s Close, adjacent to St. Patrick’s Cathedral, Dublin, and is the oldest public library in Ireland. It was built to the order of Archbishop Narcissus Marsh in 1701 and has a collection of over 25,000 books and 300 manuscripts.
Guinness Storehouse

Just outside the city center, the Guinness Storehouse is one of Dublin’s most popular tourist attractions. Visitors can experience the Guinness craft firsthand with guided tours and beer tasting. The Gravity Bar, located on the seventh floor, offers a beautiful panoramic view of Dublin.

Temple Bar

This stylish and artsy neighborhood features a variety of trendy restaurants, galleries, shopping centers, theatres and pubs. Here, you can easily find live music, free street theatre, and modern art juxtaposed with Temple Bar’s characteristic narrow, cobbled streets.

Kilmainham Gaol

Close to the Guinness Storehouse, Kilmainham Gaol is a former political prison which housed many famous independence fighters. Opened in 1796, it closed in 1924 but was restored in the 1960s to serve as a reminder of the heartbreak and heroism of Ireland’s historic fight for independence.
HOUSING
To reserve hotel accommodations for the 16th International Congress, please visit: www.mdscongress2012.org/housing/.

The housing bureau for the 16th International Congress is MCI Dublin. If you have any questions or experience problems loading the page, please contact:

MDS Housing Bureau
MCI Dublin
1 Clarinda Park North
Dun Laoghaire
Co. Dublin
Ireland
Phone: +353 01 280 2641
Fax: +353 01 280 5405
E-mail: mds2012@mci-group.com

GROUP BLOCKS – To reserve 10 or more rooms, please send your request by email to mds2012@mci-group.com

BLOOMSDAY
Basic Movement Disorders Course

Recommended Audience and Course Description
This course is specially designed for family physicians, general neurologists, internists, trainees and other clinicians interested in acquiring a basic understanding of and a clinical approach for the evaluation and management of common movement disorders. The Bloomsday Basic Movement Disorders Course will provide a foundation for participants also attending the 16th Annual International Congress of Parkinson’s Disease and Movement Disorders beginning the next day.

Bloomsday, June 16, 2012
DUBLIN, IRELAND
Venue: Royal College of Physicians of Ireland

Please note that if your residence is outside of the United Kingdom and Ireland, you must register for both the Basic Movement Disorders Course and The 16th International Congress of Parkinson’s Disease and Movement Disorders.

For more information and how to register, please visit: http://www.movementdisorders.org/education/
SAVE THE DATE

17th International Congress of Parkinson’s Disease and Movement Disorders
Sydney, Australia
June 16-20, 2013

The Movement Disorder Society